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Cancer being a second major cause of death all over the world, is most 
devastating disease and remains deadliest and of serious concern. According 
to World Health Organization (WHO) 9.6 million deaths in 2018 were due to 
cancer1 and by 2020 it is a prediction that there would be 15 million new cases 
across the globe. According to an estimation, behind one death out of six, 
cancer is the major reason.2 The limiting factor to control the cancer death is 
non-selective delivery of chemptherapeutics to tumor tissues, resulting in 
unwanted systemic exposure of anticancer drugs, causing side effects to 
healthy tissues and resistance of cancer cells. Therefore, the delivery of 
anticancer drug to target site is required to avoid undesired effects. 
Development of a drug delivery system is considered as a suitable tool, which 
can overcome these limitations and provide more satisfactory results by 
delivering the drugs to the target site.3 Such drug delivery systems (DDS) have 
been designed to modify the pharmacokinetic and physiological properties of 
drug molecules.4 For an ideal drug delivery system, it is necessary that it 
exhibits high drug loading capacity, biocompatibility, prolonged circulation time, 
protection from hydrolysis and enzymatic degradation, avoiding premature 
leakage, delivering higher doses at target site, controlled drug release, 
biodegradability and chemical stability.5 
1.1 Nanotechnology 
Nanotechnology means development of nanomaterials for the better delivery of 
drugs. In last few decades, recent developments in nanomaterials has opened 
up new areas in the treatment of cancer. Nanotechnology has addressed many 
of the limitations of conventional drug delivery system by increasing the target 
specificity, avoiding side effects and enhanced efficacy of the therapy.6,7 
Nanocarriers due to size in nanometre range have higher surface area and 
show very satisfactory physicochemical properties. Nanomaterials have 
tendency to enhance the bioavailability with prolonged circulation time and 
release the drug in a controlled manner.3 





As drug carrier nanomaterials have tendency to cross biological barriers, and 
easily enter tumors due to localized leaky vasculature. Poor lymphatic drainage 
of tumor enhances the retention time of nanomaterials. Nanostructures can be 
prepared either by physical methods such as evaporation, laser ablation and 
arc discharge or by chemical methods. The latter is considered more effective 
as it can produce nanostructures in more controlled manner and enables 
different shapes, sizes and functionalization to be attained by chemical 
reactions.8  
A variety of nanocarriers is available which include organic and inorganic 
nanomaterials. Organic nanostructures involve polymeric nanoparticles, lipid 
micelles, protein nanoconstructs, carbon dots, carbon nanotubes, graphene 
and nonodiamonds. On the other hand, inorganic nanomaterials include silica 
nanoparticles, quantum dots, super magnetic iron oxide nanomaterials, gold 
and silver nanoclusters. All these nanostructures have unique properties and 
certain modifications can even change the application and significance. 
Changes in shape and size can produce different results because interaction 
between nanomaterials and proteins is greatly dependent upon size and 
surface.9,10 
1.1.1 Inorganic Nanomaterials 
By last few years, inorganic materials have emerged as a new class in 
development of drug delivery systems and have become very important in the 
field of nanotechnology. Nanocrystals and nanowires are inorganic materials, 
which mainly involve metals and metal oxides. Inorganic nanotubes of different 
metals have also shown important applications in various research areas. 
Recent developments in the field of inorganic hybrid nanoparticles has opened 
up new dimensions as drug delivery systems in nanomedicine.8,11 A lot of efforts 
have been made to produce new biocompatible and biodegradable inorganic 
nanostructures due to their versatility and functionalization in advanced drug 
delivery systems. Due to higher adsorption capability, biocompatibility and low 
density, amorphous silica and fumed silica are potential moieties in biomedical 






Drug Administration (FDA) made them most potential and promising candidate 
among inorganic nanomaterials.12,13 
Silica is one of the most abundantly available material in nature from higher 
plants to single celled organisms. As compared to other inorganic oxides, silica 
is considered as safe and can be easily taken up by cells through endocytosis. 
Silica nanoparticles are considered very stable because they have tendency to 
withstand higher mechanical stress and degradation as compared to other drug 
delivery carriers, which require further stabilization by covalent linkers.14,15 
1.1.1.1 Mesoporous Silica Nanoparticles  
In recent past, the development of biocompatible and inorganic nano-systems 
has opened up new dimensions. Porous inorganic systems like silica have 
shown much better therapeutic effects as compared to other nanocarriers for 
the chemotherapeutics and gene delivery.16 Mesoporous silica nanoparticles 
(MSNPs) are the advanced form of silica material and were first reported by 
Mobil oil scientists in 1990s.17 Later on due the developments in 
nanotechnology and challenges in drug delivery systems it got utmost important 
as drug carrier especially in chemotherapy. MSNPs are organic templated 
inorganic materials where different surfactants can be used as organic 
templates. Figure 1 elaborates the schematic explanation for the fabrication of 
mesoporous silica nanoparticles. Surfactants have tendency to form round 
micelles by self-aggregation at critical micelle concentration (CMC) and when 
they are heated at higher concentration above CMC, hexagonal micelles are 
formed. Then silica precursors can condense at micellar surface in the 
presence of catalyst, to form organic-inorganic hybrid structures. To generate 
pores, surfactant template is removed by either calcination or extraction.18,19  
 






Figure 1: Schematic diagram elaborating the fabrication of mesoporous silica nanoparticles 
(MSNPs) 
 
As the name indicates the MSNPs consists of hexagonal pores like honeycomb 
structure and the name mesoporous is given because these pores are in meso-
range (2 nm-50 nm). In nanomedicine, the nanoscale constructs for the 
encapsulation of higher concentrations of drugs, crossing of cell membrane and 
delivery of large doses of chemotherapeutics to tumor tissues with minimum 
side effects to healthy tissues, always remains challenging.20 MSNPs have 
addressed many of the limitations of other nanocarriers.16,21 As a drug delivery 
system, they are very attractive and suitable due to their uniqueness of porous 
structure, high surface area >1000 m2/g, tuneable pore size and pore volume, 
high pore volume i.e. 1 cm3/g-1. These features of MSNPs assure high loading 
capacity for therapeutic agents and controlled release of drug.22  
MSNPs have dual functional surfaces, including internal porous surface and 
external particle surface.23,24 These surfaces can easily be functionalized to 
achieve better controlled release and conjugation of targeting ligand for target 
specificity.25 Both hydrophilic and hydrophobic nature of MSNPs make them 
suitable candidate for the entrapment of wide range of drugs. Polymeric 






MSNPs due to mechanical strength and non-toxic behaviour have become 
promising drug delivery system.21,26  
The drugs can be easily loaded to MSNPs by capillary filling or adsorption, and 
the drug release profile can be tuned depending upon the pore structure. 
MSNPs are stable in both aqueous and organic solvents, contrarily to the 
polymeric nanomaterials which interact with organic solvents and become 
unstable.27 
 
Figure 2: Illustration of MSNPs with different modifications and loading sites 
 
1.1.2 Organic Nanomaterials 
Organic nanomaterials have been extensively investigated for years because a 
wide range of organic substances are available which have very significant 
applications in nanomedicine. Basically, these are nanoconstructs, composing 
of organic substances like polymers, proteins or lipids.28  





A variety of polymeric nanoparticles has been studied as drug delivery system 
because of their biocompatibility, surface modification and targeted delivery. 
Polymeric NPs can be of either natural or synthetic origin. Albumin, hyaluronic 
acid and chitosan are widely used natural polymers for nanomedicine. Among 
the synthetic polymers, poly acrylic acid (PAA), dendrimers, poly (lactide-co-
glycolide) (PLGA), polyglycolic acid (PGA), poly lactic acid (PLA) and 
hyperbranched polymers remain applicable.29-31 Mainly the synthesis methods 
for polymeric NPs are solvent evaporation, salting out, emulsion diffusion and 
nanoprecipitation. Apart from many advantages of polymeric NPs, they have 
some limitations as well. Polymeric degradation acidity, solvent toxicity, 
reproducibility and biphasic drug release are the major challenges while dealing 
with polymeric NPs.32,33  
Lipid micelles are also useful carrier for the entrapment of different drugs. They 
are actually monolayer structures having inner hydrophobic and outer 
hydrophilic surface. However, they also have few limitations of lower 
entrapment of drugs due to small hydrophobic core and dissociation on dilution. 
On the other hand, liposomes are lipid bilayer structures and comparatively 
entrap larger amount of drugs with no direct dissociation on dilution.6 
1.1.2.1 Liposomes 
Liposomes are the most promising nanomaterials as a drug delivery carrier. 
Usually they are composed of phospholipids with two tail and one head region, 
where head group represents the hydrophilic part and tail group is fatty acid 
part, which is hydrophobic in nature. Liposomes formulation is based on lipid-
lipid interaction and by structure, they can bifurcate hydrophilic and hydrophobic 
molecules. Due to highly dynamic nature, liposomes have characteristic to 
convert to smaller compact structure when the layer is disturbed.34,35  
For the treatment of several diseases, liposomes remain under consideration 
because they can improve the therapeutic efficacy by minimizing side effects, 
rapid degradation and enhancing drug absorption. Liposomes show flexibility in 






and structures ranging from nanometers to micrometer scale.36 Bilayer 
composition can make the liposomes either permeable and low in stability or 
rigid and impermeable. By surface modification, liposomes are tailored for 
therapeutic and diagnostic purposes along with image guided drug delivery. 
Liposomes, being similar to structure of cell membrane, are unique due to their 
low immunogenicity, degradability and good biocompatibility.37 A representative 
image of liposome with hydrophilic and hydrophobic drug loading sites, is 
shown in figure 3. Liposomes are used as a drug carrier to enhance the cellular 
uptake of not only chemotherapeutics but also for the gene delivery. These 
outstanding features of liposomes in comparison to other nanocarriers resolve 
many of the issues related to drug delivery and diagnosis.38,39  
 
Figure 3: Illustration of multifunctional liposome with hydrophilic and hydrophobic moieties 
 
Despite of these salient features, liposomes also have certain drawbacks. One 
of the major limitation is opsonization of conventional liposomes by plasma 
protein and quick removal from circulation, but this issue can be resolved by 
surface modification with polyethylene glycol (PEG).40,41 Other problems of 
liposomes such as leakage and stability in circulation, have already been 
reported, but the incorporation of cholesterol to increase the cohesiveness can 
minimize the leakage problem. Cholesterol increases the rigidity of lipid 
membrane, avoids the permeation of water soluble drugs and improves the 
stability.42 





Liposomes can be classified by different factors depending upon structure, size 
and ionic nature. One classification is based on number of lipid layers such as 
multilamellar vesicles (MLVs), and unilamellar vesicles (ULVs) with further 
division in to large unilamellar vesicles (LUVs) and small unilamellar vesicles 
(SUVs). Another classification is based on the liposomal net surface charge 
such as neutral, anionic and cationic depending upon the composition and 
charges of lipids.3  
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) is an example of cationic 
lipid and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) is an anionic lipid 
while 1,2-dipalmetoyl-sn-glycero-3-phosphocholine (DPPC) is used as a 
neutral zwitterion phospholipid. The importance of cationic liposomes increased 
due to application in gene and protein delivery.43,44 
Liposomes interact with cells in different ways, mainly endocytosis, with 
phagocytic action of reticuloendothelial system. Other mechanisms are 
adsorption through electrostatic interaction between lipid bilayer and cell 
membrane, fusion by insertion of lipid layer with cell membrane an releasing 
the contents in cytoplasm and lipid exchange by transferring liposomal contents 
to cell membrane.45 
Few of the liposomal products are already in market. Doxil® being the first one 
containing doxorubicin (Dox) for the treatment of ovarian cancer and 
subsequently, DaunoXome®, Depocyt®, Myocet® and Mepcat® have been 
approved for the treatment of cancer.34 
1.1.3 Lipid Coated MSNPs 
Various studies have shown that combining two different naocarriers to form a 
new drug delivery system has produced promising results.27 As mentioned 
above, premature leakage of the drug is very critical in case of 
chemotherapeutic drug delivery. To avoid premature leakage of the drug from 
the porous structure of MSNPs, different approaches have been adopted to 






molecules and supramolecular assemblies, which can regulate the release of 
drug in a controlled manner at the target site. Some of the others, reported 
delivery systems, with either gatekeeping features or external stimuli response, 
have shown their effectiveness in non-aqueous solvents and limited application 
in physiological conditions.46 
Despite of liposomal salient features, safety of highly toxic drug during 
circulation remains a major concern. Approach of coating liposomes on MSNPs 
enhance the stability of liposomes. Figure 4 is representing drug loading and 
lipid coating of MSNPs. On one hand we can load higher amounts of drugs in 
pores of MSNPs due to larger surface area and on other hand lipid layer can 
also be used to load another drug.47 Both liposomes and MSNPs have very 
distinguishing features and by combining them very fruitful results can be 
obtained.48 Lipid coated MSNPs can enhance the biocompatibility and improve 
cellular uptake by tumor cells.42  
 
Figure 4: Representation of drug loading and lipid coating to mesoporous silica nanoparticles 
Lipid coated MSNPs have proved to be an ideal therapeutic delivery system, 
which synergistically improve drug loading, stability and controlled release of 
higher concentrations of multidrug at target site to enhance the therapeutic 
effectiveness. This synergetic effect of lipid coated MSNPs has already been 
reported as compared to non-lipid coated MSNPs.48,49 





1.1.4 Stimuli Responsive DDS 
Microenvironment of solid tumors, a well known barrier that hinders the drug 
delivery approaches, is very precisely investigated. To deal with these particular 
challenges different types of stimuli were considered as a solution to trigger the 
release of the drug to target site at specific time to enhance the therapeutic 
outcomes. In this regards, developments of smart nanoarchitectures with 
stimuli response are the hotspots by last few years in the field of 
nanotechnology.44 
Stimuli responsive drug delivery systems not only deliver the anticancer drugs 
to the target site by minimizing the side effects due to lesser exposure to normal 
tissues but also release the drugs in desired cytotoxic concentrations.50,51 In 
most of the cases tumor resistance to anticancer drug is relevant to 
subcytotoxic concentration exposure of drug to tumor.20,52 However, other 
biological intratumoral factors are also involved.53,54  
Various kinds of stimuli have been employed in drug delivery and can be 
categorized in to two main types including endo-triggered and exo-triggered. 
Among the endo-triggered, pH is most commonly used stimulus where the 
delivery of the drug is based on change in pH such as cancer and 
inflammation.10 Another endo-triggering factor is hypoxia although it is most 
challenging factor for the delivery of drug to tumor but it can be used as an 
attractive therapeutic target. Few of the drug delivery systems have already 
been reported which showed better drug delivery in hypoxia as compared to 
normoxia. Enzymatic action, temperature and oxidation-reduction reactions are 
other examples of endo-triggering stimuli. Sometimes due to rapid changes in 
biological activities of tumor these endo-triggering factors can be effected.55-57 
Therefore, exo-triggering factors offer advantages due to easy handling, time 
and location specificity.  
Main exo-stimuli are light, magnetic effect, ultrasound and external 
temperature.44,58 Many light sensitive drug delivery systems release the drug 






inadequate tissue penetration.59 Magnetic nanoparticles (MNPs) are of other 
type, which can release the drug on exposure to magnetic field60 but certain 
limitations such as low drug loading capacity and target specificity need to be 
addressed. Thermosensitive drug delivery system is also an exo-triggering drug 
delivery system where drug is released from the carrier on exposure to higher 
external temperature in the form of laser, magnetic field or water baths.61 Stimuli 
responsive drug release in a controllable manner have addressed this issue in 
recent developments but conversion of stimuli response from bench to bedside 
is very challenging due to many problems.52,62 
Ultrasound (US) remain always very important for its applications in diagnostics 
but recently it has been extensively used as a triggering factor in therapeutics 
for drug and gene delivery.  US is advantageous because of its cost 
effectiveness, portability, non-invasiveness and visualization of targeted area 
with accuracy.63 
1.1.4.1 Ultrasound Triggered DDS 
US triggered drug release has gained much more importance because it 
delivers the drug to the target site, such as tumor, and minimize the systemic 
toxicity. US responsive drug delivery is a promising method for the efficient 
treatment of certain cancers like liver tumors, which are accessible with US. In 
general US and specifically sonopration being a distinguishing feature of US, 
can be used in drug delivery systems. Sonoporation is a process by which 
microbubble mediated ultrasound cavitation can produce permanent or 
temporary pores in blood vessels wall and results in significant improvement in 
the extravascular therapeutic drug delivery. Microbubbles as hollow particles 
with gas can act as US contrasting agents due to their acoustic 
characteristics.63,64 
1.1.5 MSNPs Based Stimuli Responsive DDS 
MSNPs with a very distinguishing framework, provide a very suitable platform 
for the development of stimuli responsive drug delivery system. Ease of drug 





encapsulation in pores, sealing or capping of pore openings is a very useful 
approach for delivering toxic and therapeutic dose with precise control.65  
Stimuli response can be achieved either by chemical reactions or by physical 
or chemical changes in response to stimuli. Various techniques have been 
adopted for the preparation of MSNPs based stimuli responsive drug delivery 
systems. Mechanically drug release can be controlled with polymeric coating, 
which can close or open in specific physiological conditions of 
microenvironments.66 This approach is based on the control of hydrophobicity 
and hydrophilicity of the polymer, in hydrophobic condition preferably polymer 
adhere to MSNPs surface and in hydrophilic condition, polymer swells due to 
interaction with surrounding fluid resulting in pore opening and release of drug.  
Blocking the pore opening with nanomaterials is another approach where 
removal of these capping nanostructures is linked with stimuli such as lower pH 
of tumor, which can dissociate capping material to release the drug in controlled 
manner. Some of the reported delivery systems, with either gatekeeping 
features or external stimuli response, have shown their effectiveness in non-
aqueous solvents, resulting in limited application in physiological conditions.46 
This problem can be copped up with lipid coated MSNPs where liposomes 
along with the gatekeeping effects have better cellular uptake activity due to the 
proto cellular nature.67 
Similarly, acid-labile bonds can be used at pore opening, which hydrolyses on 
mildly acidic pH of endosomes.68,69 In other stimuli responsive MSNPs systems, 
UV light or near infrared (NIR) light can be employed as a stimulus for the 
cleavage of linkers or generation of reactive oxygen species (ROS) for site 
specific actions.70,71 Heat sensitive, thermosensitive, magnetic responsive, 
enzyme stimuli responsive, redox sensitive and US triggered drug delivery 
system based on MSNPs have already been reported for tumor targeting. Due 
to excellent textural properties stimuli responsive drug delivery has entered in 
an advanced step where use of multiple stimuli can better perform in tumor cell 
environmental conditions to be more specific and high precision for higher 






Capillary filling of MSNPs porous structure with liquid and then converting it to 
bubbles would be a good idea to entrap lower boiling point substances. 
Perfluoropentane, as an established ultrasound contrasting agent with boiling 
point 28ºC, is an ideal candidate to be loaded inside the pores. 
Perfluoropentane is used to stabilize nanobubbles in US diagnostics and due 
to hydrophobicity it remains undissolved in the blood. This nature of 
perfluoropentane has tendency to exhibit much longer lifetime on a hydrophobic 
surface. Hydrophobicity of MSNPs with larger surface area assures its 
candidature to entrap interfacial liquid inside the pores for longer time as 
compared to lipid entrapped microbubbles.24  
After entrapment of liquid perfluoropentane in porous structure, due to low 
boiling point, it can easily be converted to vapours, which exist in the form of 
bubbles and creates a large volume of gas inside the pores. Figure 4 illustrates 
stimuli responsive drug delivery system constructed of lipid coated mesoporous 
silica nanoparticles with perfluoropentane as an ultrasound responsive 
material. Advances in sonochemistry proved that ultrasound waves could 
produce either some physical effects through thermal and mechanical induction 
or chemical effects by inducing chemical reactions or combination of both. 
Induction of thermal and/or mechanical effects by ultrasound waves can be 
helpful in conversion of low boiling point liquid to bubbles, disruption of these 
bubbles and exerting pressure on the carrier to release the drug.73,74 
Lipid coating of MSNPs, as a gatekeeper at pore opening of MSNPs, provides 
an intact barrier against the premature release of the drug and liquid inside 
pores in inert conditions75 but application of ultrasound waves on such carriers 
plays an important role on thermal sensitive liposomes via thermal effects 
leading to opening of the MSNPs pores. So the combined energy of mechanical 
and thermal effects on vaporization of liquid inside pores and lipid coating 
enhance the release of the drug.76 






Figure 5: Schematic representation of ultrasound triggered release from lipid coated 
mesoporous silica nanoparticle 
 
1.2 Ultrasound 
Ultrasound being a remarkable approach in biomedicine, has emerged as an 
important tool which has shown many applications including, release of the drug 
from carriers, effects on opening of blood brain barrier, thermal therapies and 
many others.74,77-79 As an exogenous stimulus, ultrasound is very 
advantageous because of noninvasiveness, cost effectiveness and non-
ionizing features. Moreover, the penetration depth can also be adjusted 
according to frequency and exposure duration, resulting in more specific local 
outcomes and minimizing the adverse effects.80 Ultrasound can produce two 
different kinds of biological effects such as thermal and mechanical. Cavitation 
is most commonly used mechanical effect of ultrasound in enhanced drug 






the acoustic pressure, results in destruction of gas bubbles. These nuclei can 
be either gas bubbles,82 gas stabilizing solid nanoparticles83,84 or droplets.85 
Ultrasound can be used not only for triggered release of the drug but also for 
the tracking of drug carriers in the body. It is evident that US with mechanical 
index (MI)<0.5 is used for prolonged imaging because at this acoustic energy 
the bursting of contrasting bubbles is lesser but MI>0.5 causes the destruction 
of ultrasound contrasting agents like perfluoropentane and results in the 
diffusion of gas into the surrounding area. An instantaneous bursting of 
perfluorocarbons with MI 1.4 has also been reported.86,87 This agent destruction 
is considered as a limiting factor for imaging but this limitation can be converted 
to beneficence, and triggered release of drug from carrier can be achieved at a 
desired site. The release of the drug from carrier is due to mechanical and 
thermal effect of the ultrasonic waves.88 However it is very difficult to identify 
either alone in biological applications. The thermal effect of US irradiation is 
evident, which has been used for the diagnostic and therapeutic purposes such 
as reduction in joint stiffness, blood flow changes, muscle spasm and many 
others. US due to its hyperthermic effects with combination of either 
radiotherapy or chemotherapy, is very useful in cancer treatment.89 Although 
intensity of thermal effects depends upon many factors but significant 
hyperthermia effects to various tissues has been reported.90,91 
1.3 Hypoxia 
Hypoxia is a condition where the tissues are deprived of oxygen, resulting in 
low oxygen tension and is a common feature of solid tumors.92 It is established 
that hypoxia is responsible for tumor progression and metastasis, including 
breast cancer metastasis.93 In cancer therapy, being a negative factor, hypoxia 
has a strong association with enhanced malignancy because of resistance to 
chemotherapy and ionized-radiation.94-96 There is a strong evidence that 
hypoxia inducible factor and alteration in tumor metabolism linked with carbonic 
anhydrase enzyme IX and XII, can play a vital role in tumor metastasis and 
progression.93 





1.3.1 Carbonic Anhydrase IX (CA-IX) Enzyme 
Carbonic anhydrase IX (CA-IX) is a protein located in cell membrane of cancer 
cells and which is rarely expressed in normal tissues but overexpressed under 
hypoxic conditions.97,98 Carbonic anhydrases are zinc metalloenzymes 
consisting of 15 different isozymes, which exhibit different cellular localization, 
catalytic activities and distributions in tissues. Few of isozymes such as 
carbonic anhydrase I, II, III, VII and XIII are associated with cytosol and others 
such as IV, IX, XII and XIV reside in cellular membrane. The major activity of 
carbonic anhydrase enzymes is to catalyze reversible reaction between water 
and carbon dioxide to produce bicarbonates and proton.99,100 
CO2 + H2O ↔ HCO3¯ + H+ 
Carbonic anhydrases play an important role in pH control and CO2 
homeostasis, biosynthetic reactions based on HCO3¯ and CO2, electrolyte 
secretions and CO2 transportation between lungs and tissues. By recent 
studies, it is revealed that hypoxic conditions of solid tumors trigger various 
gene expression, carbonic anhydrase IX is one of them. The over expression 
of carbonic anhydrase IX in hypoxic tumor is associated with poor prognosis 
and tumor aggression, resulting in radio and chemotherapy resistance.100-103  
CA-IX transports intracellular CO2 to extracellular environment after converting 
it to carbonic acid and proton. An over expression of CA-IX results in 
extracellular acidic environment which has already been reported by different 
cell lines in hypoxic conditions. In recent times CA-IX being endogenous marker 
for different tumors, has been under investigation to overcome the challenges 
related to chemical markers administration and invasive techniques before 
biopsy.92,104,105 As homeostatic activity, CA-IX enzyme maintains the 
intracellular pH (pHi) neutral to slightly basic and extracellular pH (pHe) 
acidic.106 An illustration of different mechanisms involved in pH regulation, with 







Figure 6: Ionic exchange and pH regulation mechanisms of cancer cells 
 
Most chemotherapeutics are weak electrolytes and their uptake to the cells is 
normally by passive diffusion but extracellular acidic environment results in 
ionization of such drugs. The permeability of plasma membrane to ionized 
substances is very low due to ion trapping and consequently lesser cellular 
uptake of drugs.107 According to this ion trapping model, weakly basic drugs 
such as doxorubicin, daunorubicin and mitoxantrone are highly accumulated in 
extracellular acidic environment with lower toxicity due to limited uptake of the 
drug. However, weakly acidic drugs such as chlorambucil and melphalan can 
easily be taken up to intracellular neutral or relative higher pH environment.108 
Different approaches have been adopted to alter internal and external pH of 
solid tumors, for different anticancer drugs to enhance their therapeutic effects. 
Extracellular pH enhancement was found with improved cytotoxic effects of 
weakly basic drugs such as topotecan and paclitaxel.109 A delay in tumor growth 
with doxorubicin, after treatment with sodium bicarbonate solution to enhance 
extracellular pH, has already been reported. Carbonic anhydrase inhibition has 
shown synergistic effects in combination with chemotherapeutic agents.110,111 
Figure 7 is an illustration of an advanced drug delivery carrier with carbonic 





anhydrase enzyme inhibitor loaded in lipid layer and doxorubicin in mesoporous 
silica for co-delivery. Carbonic anhydrase IX inhibition by antibodies or specific 
inhibitors, on one hand can enhance the effects of weakly basic drugs and on 
the other hand reduce the metastatic phenotype due to control of pH balance 
in tumor cells.112 
 
Figure 7: Representation of lipid coated mesoporous silica nanoparticle designed for co-






1.4 Aims and Objectives 
The purpose of this study was to develop a drug delivery system, which exhibits 
biocompatibility, high loading capacity, no premature leakage, site-specific drug 
delivery and good cellular internalization. Nanoconstructs were comprised of 
mesoporous silica nanoparticles, coated with lipid layer to deliver weakly basic 
drugs like doxorubicin with higher internalization in tumor cells. Specifically, by 
combining it with carbonic anhydrase IX inhibitor under hypoxic conditions to 
avoid ionization of drug for better cytotoxic effects.  Furthermore, an ultrasound 
responsive smart delivery system was developed for targeted release, where 
the release of the drug was dependent on ultrasound. 
The important aspects covered under this work are as follow 
 Fabrication of mesoporous silica nanoparticles with larger surface area 
and development of lipid coated mesoporous silica nanoparticles to 
encounter lower drug delivery and premature drug release 
 Physicochemical characterization for size, surface charge and surface 
area and morphological assessment with electron microscopy. 
 In-vitro drug release evaluation and cytotoxic studies with a comparison 
of lipid coated and bared mesoporous silica nanoparticles for cellular 
internalization. 
 Development of ultrasound responsive lipid coated mesoporous silica 
nanoparticles for triggered release and in-vitro stability evaluation 
 Comparison of In-vitro cytotoxic effects and cellular uptake studies 
 Incorporation of carbonic anhydrase-IX inhibitor into lipid coated 
mesoporous silica nanoparticles with doxorubicin to determine 











2  Materials & Methods 
 






List of Materials 
 
Agarose Merck KGaA, Germany 
APTES Sigma Aldrich Chemie GmbH, Germany 
CA-IX (H-11) sc-365900  Santa Cruz Biotechnology, Inc, Germany 
Carbon coated copper grid  PLANO GmbH, Germany 
Chloroform VWR International GmbH, Germany 
Chlorpromazine Alpha Aesar GmbH & Co. KG., Germany 
Cholesterol Sigma Aldrich Chemie GmbH, Germany 
Coverslip Gerhard Menzel B.V. & Co. KG., Germany 
Cuvette (DLS) Malvern Instruments Ltd, UK 
CTAB Carl Roth GmbH & Co. KG , Germany 
DAPI Sigma Aldrich Chemie GmbH, Germany 
DMEM Biochrom GmbH, Germany 
DMSO Acros Organics B.V. B.A., Belgium 
DOTAP Lipoid GmbH, Germany 
Doxorubicin Fluorochem Ltd, United Kingdom 
DPPC Lipoid GmbH, Germany 
Ethanol Carl Roth GmbH & Co. KG , Germany 
Fetal calf serum PAA Laboratories GmbH, Germany 
Filipin III Sigma Aldrich Chemie GmbH, Germany 
FITC Sigma Aldrich Chemie, Germany 
FluorSave Calbiochem Corporation, USA 
Glass slide Gerhard Menzel B.V. & Co. KG., Germany 
HCl Carl Roth GmbH & Co. KG , Germany 






AFM Probe: HQ:NSC14/AL_BS MikroMasch, Estonia 
AFM Probe: HQ:NSC16/AL_BS MikroMasch, Estonia 
MDA-MB 231 ATTC® , USA 
Methanol Carl Roth GmbH & Co. KG , Germany 
MilliQ water  Millipore Corporation, USA 
MTT Sigma Aldrich Chemie GmbH, Germany 
NaHCO3 Carl Roth GmbH & Co. KG , Germany 
NaOH Carl Roth GmbH & Co. KG , Germany 
Nitrogen gas Praxair GmbH, Germany 
Pen-strep Sigma Aldrich Chemie GmbH, Germany 
Formaldehyde 
Alpha Aesar GmbH & Co. KG., Karsruhe 
Germany 
Petri dishes Sarstedt AG & Co.,Germany 
PFP abcr GmbH, Germany 
Polycarbonate Membrane Whatman plc, Maidstone, UK 
Protein assay kit  Bio-Rad, Munich, Germany 
RPMI Biochrom GmbH, Germany 
Sample cells (BET) BEL Europe, GmbH, Germany 
SKBr-3 ATTC® , USA 
Streptomycin Sigma Aldrich Chemie GmbH, Germany 
Syringe BD GmbH, Germany 
Syringe Filter Whatman plc, UK 
TEA Merck KGaA, Darmstadt, Germany 
TEOS Carl Roth GmbH & Co. KG , Germany 
Triton X100 Sigma Aldrich Chemie GmbH, Germany 
Tubulin (sigma) Sigma Aldrich Chemie GmbH, Germany 
Uranyl Acetate Sigma Aldrich Chemie GmbH, Germany 





12 well plate Nunc GmbH & Co. KG, Germany 
6 well plate Sarstedt AG & Co.,Germany 









List of Devices  
AFM JPK instruments AG, Berlin 
Autoclave, Tuttnauer 3850 ELC Tuttnauer GmbH, Germany 
Bath Sonicator Elma Schmidbauer GmbH, Germany 
BELsorp mini II BEL GmbH Europe, Germany 
Centrifuge machine  Eppendorf Int., Germany 
Centrifuge machine-Beckman 
J2-21 
Beckman Coulter GmbH, Germany 
CLSM Carl Zeiss Microscopy GmbH, Germany 
Cryo-TEM: Libra 120 Plus Carl Zeiss Microscopy GmbH, Germany 
Extruder-Avanti Mini Avanti Polar Lipids Inc, USA 
Luminometer: 96 well reader MBG, Labtech, Germany 
Freeze dryer, Christ Beta 1 
Martin Christ Gefriertrocknunganlagen 
GmbH, Germany 
FTIR- Alpha-ATR Bruker GmbH, Germany 
Incubator, CO2, HeraCell Heraus GmbH & Co. KG., Hermany 
ISciTive Hypoxic Workstation Baker Ruskinn, UK 
Laminar Flow Hood: Class II NuAire Inc., USA 
Magnetic stirrer CAT Scientific USA 
Rotary evaporator 
Heidolph Instrumenst GmbH & Co. KG., 
Germany 
STEM: JEOL 2200FS JEOL, Ltd., Japan 
TEM, JEOL 3010 JEOL, Ltd., Japan 
Trans Blot Turbo blotting system 
(Bio-Rad) 
Bio-Rad Laboratories GmbH, Germany 





Ultrasound device: Ezono300  eZono AG, Germany 
UV-visi spectrophotometer: 
UVmini-1240 
Shimadzu Corp, Japan 
Vario MICRO cube 
Elementar Analysensysteme GmbH, 
Germany 









2.1.1 MSNPs Fabrication 
Mesoporous silica fabrication is based upon two parameters including the 
dynamics of surfactant for assembly formation in the form of micelles and 
condensation ability of inorganic oxides to form thermostable nanostructure.  
2.1.1.1 Cetyltrimethylammonium Bromide (CTAB)  
As a template agent CTAB is most commonly used surfactant in the synthesis 
of MSNPs. It is cationic in nature and a quaternary ammonium surfactant with 
molecular weight 364.45 g/mol. CTAB is a white powder with alkyl chain of 16 
carbons. Its melting point is ranging from 237-240ºC. CTAB used here was > 




2.1.1.2 Tetraethylorthosilicate (TEOS)  
TEOS is used as a silica precursor in MSNPs preparation. Its molecular formula 
and molecular mass are (C2H5O)4 Si and 208.33 g/mol respectively. TEOS is a 
colorless liquid with a density of 0.933 g/ml and most prevalent silicon alkoxide. 
It intereacts with water to produce Si-O-Si by hydrolysis and condensation. The 
purity of TEOS used in this work was > 99%. Due to its anionic nature it can 
react with cationic template to form organic-inorganic structures. 







2.1.2 Liposomal Preparation 
For the liposome preparation, three different lipids were used. These lipids 
were >99% pure and dissolved in chloroform:methanol (2:1 v/v) at the final 
concentration of 10mg/ml.  
2.1.2.1 DPPC 
1,2-dipalmetoyl-sn-glycero-3-phosphocholine is a zwitterion, which consists of 
polar head group with two saturated fatty chains of palmitic acid. Its molecular 
weight is 734.053 g/mol with chemical formula (C20H40)2 NO8P. The phase 




1,2-dioleoyl-3-trimethylammonium-propane is a cationic lipid with unsaturated 
long chain fatty acids. Its transition temperature is <5ºC. DOTAP has molecular 









Cholesterol is a very important part of lipid membranes and liposomes. It is 
used as a stabilizer, by reducing the fluidity of lipid layer resulting in modulation 




2.1.3 Loading Materials 
2.1.3.1 Doxorubicin (Dox) 
Doxorubicin is widely used chemotherapeutic in various types of cancers 
especially breast cancer. It is an anthracycline and also known with name of 
Adriamycin. Doxorubicin shows its cytotoxic action by damaging DNA after 
intercalation into DNA and preventing its replication. It also inhibits progression 





of topoisomerase II which has a critical role in DNA function. It is hydrophobic 
in nature but its hydrochloride salt is water soluble. Here we have used >95% 
pure doxorubicin hydrochloride as a model drug. It is red to orange powder with 




2.1.3.2 Perfluoropentane (PFP)  
PFP is a fluorocarbon having molecular formula C5F12 and boiling point 29ºC. 
Due to its ultrasound responsive nature it plays a vital role in development of 
ultrasound based drug delivery systems. Its molecular weight is 288.05 g/mol 
and density of 1.6 g/ml. PFP used in this work was 90% pure and because of 









2.1.3.3 Carbonic Anhydrase IX (CA-IX) Enzyme Inhibitor 
Carbonic anhydrase IX inhibitor used in this study is a cell membrane 
permeable benzenesulfonamide. It is a white solid and soluble in organic 
solvents. The molecular formula and molecular weight of the compound are 
C13H22N4O5S and 336 g/mol respectively. It shows specific inhibiting activity for 
human carbonic anhydrase isoforms such as hCA-I, hCA-II, hCA-IX and hCA-
XII. Its effectiveness at lower concentrations especially for CA-IX (Ki 0.9 nM) 
and CA-XII (Ki 5.7 nM) is advantageous to other CA-IX inhibitors. The purity of 











2.2 Experimental Section 
2.2.1 Development of Carriers 
2.2.1.1 Preparation of Liposomes 
Liposomes were prepared with thin layer hydration technique with a slight 
modification of the method already been reported.113,114 Liposomes were 
composed of DPPC, Cholesterol and DOTAP at molar mass ratio of 85:12:3. In 
brief, definite quantity of lipids dissolved in chloroform:methanol (2:1 v/v) was 
taken in round bottom flask and after dilution the organic solvents were  
evaporated subsequently under vacuum pressure. Rotary evaporator Heidolph 
Laborota 4000 efficient (Heidolph Instruments, Schwabach, Germany) with 
bath temperature 45ºC was used for reducing pressure until a thin lipid layer 
was formulated. After complete hydration of lipid film with PBS (pH 7.4) buffer, 
the mixture was sonicated in ultrasound bath at 45ºC for 15 min. For uniform 
size distribution the lipid mixture was extruded through a polycarbonate filter of 
100 nm pore size at transition temperature.40  
2.2.1.2 Fabrication of MSNPs  
For the synthesis of MSNPs, the four main components are source of silica 
(TEOS), organic template as a structure directing surfactant (CTAB), catalyst 
bases such as sodium hydroxide (NaOH), sodium bicarbonate (NaHCO3) and 
triethanolamine (TEA) and solvent (Water). Fabrication of MSNPs is based on 
hydrolysis and condensation of TEOS in the presence of water and CTAB in 
basic environment. CTAB is a cationic surfactant which can form hexagonal 
micelles by heating its aqueous solution at higher concentration than CMC. 
TEOS is an inorganic material, which interacts electrostatically with CTAB. In 
basic environment, TEOS exists as negatively charged ions and reacts with 
positively charged ions on cationic surfactant of hexagonal micelles. Base 
catalysis helps hydrolysis and condensation reaction between water, TEOS 





and CTAB. MSNPs were fabricated by a modified method which has already 
been reported.115  
In short a definite amount of CTAB and 350 µl of 2 M NaOH solution were added 
to 48 ml of purified deionized water and stirred at 350 rpm for 2 hrs at 80ºC. 
When the solution became pellucid and CTAB was completely dissolved in the 
form of hexagonal micelles, 500 µl of TEOS was added dropwise. The above 
mixture was stirred at same speed overnight in an inert environment at 80ºC. 
The molar concentrations in mmoles of CTAB:TEOS:NaOH:H2O were used as 
0.274-1.28:2.2:0.7:2667 respectively. The molar ratios of CTAB/TEOS ranging 
from 0.12-0.58 were used to prepare different sized particles. To check the 
effect of pH on MSNPs synthesis, a different catalytic base TEA was also used. 
Same molar ratio formulations were also prepared by using TEA and NaHCO3 
as catalysts instead of NaOH. The molar concentrations with TEA were as 
CTAB: TEOS: TEA: H2O were used as 0.274-1.28:2.2:0.56:2667. The pH of the 
final solutions with NaOH and TEA were 11.04 and 8.92 respectively.  
2.2.1.2.1 Surfactant Removal 
The milky solution was collected and centrifuged at 16000 g for 20 min and 
pellet was obtained as surf-MSNPs. These surf-MSNPs were suspended in 
ethanol:HCl (19:1 v/v) and extraction was performed overnight at 80ºC in oil 
bath. MSNPs dispersion was again centrifuged at above mentioned force and 
time. For complete removal of surfactant, the particles were washed two times 
with ethanol and two times with water to obtain pure MSNPs. The particles were 
lyophilized and stored at -20ºC. 
2.2.1.3 Surface Modified MSNPs Preparation 
FITC (Fluorescein-5 isothiocyanate) and APTES (3-aminopropyl 
triethoxysilane) were used for the fluorescence and surface modification 
simultaneously. 1.1 mg of FITC and 2.4 µl of APTES were dissolved in 0.6ml 
ethanol under nitrogen flow and allowed to stir for 2 hr. After stirring TEOS was 






CTAB solution dropwise. The molar concentrations were similar as used in the 
simple MSNPs. 
2.2.1.4 Lipid Coated MSNPs 
Before extending our experiments to the coated Dox-MSNPs, we initially coated 
lipid to unloaded MSNPs. 70 µl of above mentioned liposomes were mixed with 
1 mg of lyophilized MSNPs by pipetting. The mixture was further sonicated for 
10 min and incubated at room temperature overnight. Electrostatic interaction 
between cationic lipid layer and anionic MSNPs surface along with liposomal 
surface tension resulted in the lipid coating of MSNPs. Lipid coated MSNPs 
were centrifuged at 16000 g for 30 min to remove the extra liposomal contents 
as supernatant. Pellet was suspended in purified water and lipid coating was 
confirmed with dynamic light scattering (DLS) and laser doppler velocimetry 
(LDV) by size and the shift of zeta potential. 
2.2.1.5 Preparation of Dox-MSNPs 
As Dox exists as a positive charge moiety at neutral pH, so it can easily be 
loaded in the porous structure of negatively charged MSNPs due to electrostatic 
interaction.116 To evaluate the loading capacity of MSNPs 2.5 mg of lyophilized 
MSNPs were suspended in 6ml of purified water, sonicated for 5 min for uniform 
dispersion and after adding different amounts of Dox including 1.5 mg, 3 mg, 6 
mg and 12 mg, suspensions were stirred overnight at 350 rpm at room 
temperature. Drug loaded MSNPs were centrifuged at 16000 g for 30 min and 
pellet was washed three times with water to remove extra Dox on surface of the 
MSNPs. Subsequently, the supernatants were collected and measured with 
UV-visible spectrophotometer. The amount of entrapped drug was then easily 
calculated by subtracting unentrapped drug from the total amount of drug. 
Finally, the drug loaded MSNPs were redispersed in water and lyophilized.  
2.2.1.6 Preparation of Lip-Dox-MSNPs 
To coat Dox-MSNPs with lipid layer, weighed amounts of MSNPs loaded with 
Dox were mixed with liposomes as mentioned above in section 2.2.1.4. 





2.2.1.7 Preparation of PFP-Dox-MSNPs and Lipid Coating 
The above prepared dried Dox-MSNPS corresponding to 2.5 mg MSNPs were 
mixed with 200 µl of ultrasound contrasting material, perfluoropentane (PFP) 
and sonicated for a short time at 4ºC, to enhance the capillary filling so that 
liquid PFP can penetrate inside the pores, and incubated in a cold environment 
for 24 hrs. After incubation period the extra liquid PFP outside the pores, was 
evaporated at room temperature and leaving behind PFP-Dox-MSNPs in dried 
form. 
Previously optimized mass ratio of MSNPs to liposomes (1:0.7) was used to 
coat the liposome. After addition of definite quantity of liposomes to PFP-Dox-
MSNPs the mixture was pipetted frequently and shacked well to coat the 
liposomes on the surface of particles to obtain Lip-PFP-Dox-MSNPs.117 For 
comparative studies non-ultrasound reactive Lip-Dox-MSNPs were used as 
mentioned in section 2.2.1.6. 
2.2.1.8 Preparation of CA-IX inhibitor Liposomes (Lipc) 
CA-IX inhibitor loaded liposomes (Lipc) were prepared by using same method 
as described in section 2.2.1.1. Same molar mass ratios of DPPC, cholesterol 
and DOTAP were used with an addition of CA-IX inhibitor. Briefly 20 nmoles of 
CA-IX inhibitor dissolved in methanol were added to lipid solutions followed by 
same procedure in section 2.2.1.1. The final concentration of CA-IX inhibitor in 
liposomes was 20µM. 
2.2.1.9 Preparation of Lipc-Dox-MSNPs  
For Lipc coating of MSNPs, previously optimized molar mass ratio of 
MSNPs:liposome (1:0.7) was used by adopting same procedure as mentioned 
in 2.2.1.6. The important parameter for CA-IX inhibitor concentration was kept 
in mind so that even after dilution, its concentration remains higher than the 








For the characterization of MSNPs different techniques has been used. Initial 
characterization was done with dynamic light scattering (DLS) and Laser 
Doppler Velocimetry (LDV) for particle size and surface charge. Morphological 
studies were done with microscopic techniques like, atomic force microscope 
(AFM), transmission electron microscope (TEM), cryo transmission electron 
microscope (Cryo-TEM) and scanning transmission electron microscope 
(STEM). Elemental analysis and fourier transform infrared (FTIR) spectroscopy 
were used to characterize surfactant removal and surface modification. For 
surface area, pore size and pore volume Brunauer Emmett Teller (BET) was 
used. UV-visible spectrophotometer was used for the quantification of amount 
of drug loading and release profiles. Ultrasound characterization and triggered 
release was done with portable ultrasound device. Cell culture experiments 
were performed for the cytotoxic evaluation and confocal laser scanning 
microscope (CLSM) imaging for cellular uptake analysis.  
2.2.2.1 Physicochemical Characterization 
2.2.2.1.1 Dynamic Light Scattering (DLS) 
Initially sizes of nanocarriers were characterized by dynamic light scattering. 
with the help of Zetasizer NanoZS (Malvern Panalytical, Germany). Light 
scattering angle was set at 173º with HeNe laser at wavelength of 633 nm. For 
each measurement, the formulations were diluted with 1% phosphate buffer 
saline (PBS) at 1:100. The adjustment of attenuator was set to automatic mode. 
Each formulation was measured in triplicate and each measurement consists 
of 15 runs. Data is presented as ZAverage of three independent formulations 
with standard deviation (intensity distribution). Similarly, polydispersibility index 
(PDI) was measured in the form of average of three independent formulations 
with standard deviation. 
 





2.2.2.1.2 Laser Doppler Velocimetry (LDV) 
Laser Doppler Velocity (LDV) was used for zeta potential measurements with 
scattered light measured at an angle of 17º with Zetasizer NanoZS (Malvern 
Panalytical, Germany). Same dilutions of different formulations, as mentioned 
above, were used for surface charge characterization. The measurements were 
done for three different independent formulations of MSNPs and liposomes. 
Each formulation was measured in triplicate and each measurement consists 
of 15-100 runs and is presented as average with standard deviation. 
2.2.2.1.3 Elemental Analysis 
We have used CTAB as an organic template and porous structure depends 
upon the removal of surfactant, leaving behind pores. As CTAB contains 
carbon, hydrogen bromine and nitrogen (Formula: C19H42BrN), the presence or 
absence of such elements is a good tool to analyze surfactant removal. 
Elemental analysis, based on combustion, was performed with vario MICRO 
cube (Elementar Analysensysteme GmbH, Germany) to evaluate the amount 
of surfactant before and after washing. Tin boats with weighed amounts of 
samples were subjected to combustion and finally results were collected as 
% age of relevant elements. 
2.2.2.1.4 Surface Area Measurement 
For surface area characterization along with pore size, pore volume and its 
distribution, gas adsorption measurements were performed with BELSorp mini 
II (BEL GmbH Europe, Germany). It is a quantitative process of nitrogen 
physiosorption by adsorption-desorption isotherm, which describes the amount 
of nitrogen adsorption-desorption at constant temperature as a function of 
nitrogen partial pressure.  The Brunauer Emmett Teller (BET) is most 
commonly used method for the determination of surface area of porous 
structures by gas adsorption. Samples were pretreated at 120ºC at low 
pressure for 2 hrs to remove all the impurities and water contents. Then 
weighed amounts of pretreated samples were subjected to surface area and 






Barrett-Joyner-Halenda (BJH) model. Two inert gases Nitrogen and Helium 
were used for purging and adsorption.   
2.2.2.1.5 Fourier Transform Infrared (FTIR) spectroscopy 
FTIR spectroscopy of different samples was performed with Bruker-ALPHA 
ATR-FTIR (Bruker, Germany). For the assessment of surfactant removal, a 
small amount MSNPs with and without surfactants were placed on ATR crystal 
to get spectrum. Similarly, spectrums were obtained for the surface modified 
MSNPs (FITC-APTES) and lipid coated MSNPs.  
2.2.2.2 Morphological Studies 
2.2.2.2.1 Electron Microscopy 
Electron microscope utilizes electron beam for imaging the specimen. The 
basic principle of electron microscopy is more or less similar to light microscope 
with the difference of electron instead of light. It allows to take images with much 
higher magnification for detailed morphological studies. 
2.2.2.2.1.1 Transmission Electron Microscopy (TEM) 
The TEM micrographs were taken with transmission electron microscope at 300 
kV accelerated voltage (TEM JEOL 3010, 300 kV) at the Philipps University 
Marburg. Copper grids were used for the placement of the samples and 
observed under electron transmission to get the images. Due to non-conducting 
behavior of particles, samples were coated with a thin layer of carbon. For 
negative staining, lipid coated MSNPs were mixed in 1:1 v/v with 2 % uranyl 
acetate. After incubation for 30 min the lipid containing samples were also 
observed with above mentioned specifications. Another set of lipid coated 
MSNPs, after US irradiation, was examined at the MLU Halle Wittenberg with 
an EM 900 TEM (Carl Zeiss Microscopy GmbH, Oberkochen, Germany, 
acceleration voltage 80kV). 
 





2.2.2.2.1.2 Cryogenic Electron Microscopy (Cryo-EM) 
Cryo-TEM micrographs were taken at the MLU Halle Wittenberg. Vitrified 
specimens were prepared using a blotting procedure, performed in a chamber 
with controlled temperature and humidity using an EM GP grid plunger (Leica, 
Wetzlar, Germany). The sample dispersion (6 μl) was placed onto an EM grid 
coated with a holey carbon film (Cflat, Protochips Inc., Raleigh, NC). Excess 
solution was then removed by blotting with a filter paper to leave a thin film of 
the dispersion spanning the holes of the carbon film on the EM grid. Vitrification 
of the thin film was achieved by rapid plunging of the grid into liquid ethane held 
just above its freezing point. The vitrified specimen was kept below 108 K 
during storage, transferred to the microscope and investigated. Specimens 
were examined with a Libra 120 Plus transmission electron microscope (Carl 
Zeiss Microscopy GmbH, Oberkochen, Germany), operating at 120 kV. The 
microscope was equipped with a Gatan 626 cryotransfer system. Images were 
acquired using a BM-2k-120 dual-speed on-axis SSCCD camera (TRS). 
2.2.2.2.1.3 Scanning Transmission Electron Microscopy (STEM) 
STEM is a technique which combines both principles of scanning by scanning 
electron microscopy (SEM) and transmission of TEM. A highly focused beam 
was applied to the specimen and for scanning similar to SEM operation. 
Transmitted electrons are then collected to form transmission images in the 
form of bright field images. STEM measurements were carried out in an 
aberration corrected JEOL JEM 2200FS operating at 200 kV. A high angle 
annular dark field (HAADF) detector was used in order to retrieve image 
intensities proportional to atomic number of the elements in the sample. 
2.2.2.2.2 Atomic Force Microscopy (AFM) 
Small amount of diluted sample was placed on silica surface, fixed on a glass 
slide by double tape. The extra liquid was removed after the settlement of the 
particles and dried under air. Nanowizard 3 Nanoscience (JPK Instruments) 






measure the atomic force microscopy. Amplitude signals of cantilever in trace 
direction and height signal in retrace direction were used to obtain the images.  
2.2.2.3 UV-Visible spectroscopy 
UV-Visible spectroscopy is a qualitative and quantitative analysis technique, 
which shows a linear relationship between absorbance and concentration of the 
samples. In this study, we have used UVmini-1240 (Shimadzu Corp, Japan) at 
482 nm and 495 nm for water and PBS pH 7.4 to find the unknown 
concentrations of Dox for drug loading and drug release profiles. 
2.2.2.4 In-Vitro Drug Release 
To evaluate the drug release behavior from MSNPs and Lip-Dox-MSNPs in-
vitro drug release studies were performed. MSNPs containing 3 mg of Dox were 
suspended in previously activated dialysis tubes with molecular weight cut off 
(MWCO) value of 6000-8000 Daltons (Repligen Europe B.V. Breda, 
Netherlands). The tubes with 1/3 air were sealed with clips and further 
suspended in PBS buffer (pH 7.4) medium under air sealed environment. The 
medium was shaken on magnetic stirrer at 100 rpm at 37ºC. At different 
intervals, 3ml of the sample was taken and fresh medium was added.118 The 
concentration of Dox in sample was measured with UV-visible 
spectrophotometer at 482 nm. The same procedure was adopted with Lip-Dox-
MSNPs and amount of drug release was measured. 
2.2.2.5 Ultrasound Characterization 
2.2.2.5.1 Stability Studies of Lip-PFP-Dox-MSNPs 
The ultrasound contrast studies were performed with the help of commercially 
available clinical device eZono 3000 (eZono AG, Germany) equipped with a 
probe having a center frequency of 3.5 MHz with MI 0.7 which are approved 
specifications by FDA. For ultrasound contrast characterization, we have used 
a self-designed model of agar phantom with a circulating set of tubes to imitate 
the soft tissues and blood vessels. To mimic the movements in the body, 
system was fitted to peristaltic pump for continuous but pulsatile movement of 





fluid to one direction. Contrast can easily be visualized on the screen attached 
to probe and the overall layout of the model is shown in figure 8.  The distance 
between probe and silicon tube in agar phantom model was kept 9 cm.  
  
Figure 8. Experimental agar phantom model for US contrast evaluation of PFP loaded drug 
carrier. 
An amount 100 ml of PBS buffer at 37ºC was circulated in silicon tube and 100 
µl of PFP loaded MSNPs sample was added to check the contrast in dynamic 
conditions. The stability for ultrasound contrast due to entrapped PFP inside 
the pores was studied for 120 hrs by adding 100 µl of sample at different time 
intervals.  
Apart from US contrast stability, to observe the role of PFP inside the pores of 
MSNPs & gatekeeping effect of lipid layer on the stability and drug retention 
capacity of MSNPs, premature drug release test was performed under inert 
conditions. As our hypothesis was to trigger the release of drug by US-
irradiation resulting in the conversion of liquid PFP to gaseous form so it was 
necessary to observe the effects of PFP on the release of drug in the absence 
of US radiations. Dox-MSNPs, Lipid-Dox-MSNPs and Lip-PFP-Dox-MSNPs 
were subjected to leakage test for 10 days. Above mentioned formulations were 
suspended in PBS 7.4 and incubated under static conditions at 4ºC. Samples 
were taken at different time intervals and amount of drug released was 






2.2.2.5.2 Ultrasound Triggered Drug Release 
In vitro drug release was performed by using another self-made agar phantom 
having a cavity of 15 ml in the middle. In brief the middle cavity was filled with 
PBS buffer and a definite amount of Lip-PFP-Dox-MSNPs was added to it. The 
mixture was stirred at a speed of 150 rpm and was subjected to ultrasound 
radiations with a probe (12 MHz, MI 1.4). Samples were taken at different time 
intervals and same amount of fresh medium was added after each sample. 
After centrifugation supernatant was collected and the amount of drug release 
was measured with the help of UV-Vis spectrophotometer. To compare the 
triggering effect of ultrasound radiations, the same procedure was adopted for 
Dox release from Lip-Dox-MSNPs without application of ultrasound. 
2.2.2.5.3 Measurement of Gas Produced by Vaporization 
To confirm the availability of liquid PFP inside pores and gas production, we 
measured the volume of gas produced with US-irradiations in a double syringe 
close system connecting to each other by a two way Luer lock stopcock as 
shown in figure 9.119 Briefly, 2 ml of Lip-PFP-MSNPs in purified water with final 
concentration of 2.5 mg/ml was contained in 10 ml Hamilton gastight syringe. 
After connecting to two way Luer lock stopcock, the air was removed by 
depressing the plunger and stopcock was closed. Another 250 µl syringe 
containing 20 µl of water was connected to other side of the lock to avoid any 
air pocket in the system. By withdrawing the plunger of large syringe to two or 
three times of the volume of the dispersion, vacuum was created. The plunger 
was held at that position for 2 min and after releasing the plunger, it returned to 
the volume higher than original volume. Then the amount of air produced was 
measured as an air pocket between plunger of large syringe and dispersion. 
 






Figure 9: A double syringe close system connected via a two-way Luer lock stopcock. 
 
2.2.2.6 Cell Culture Experiments 
The epithelial adenocarcinoma breast cancer cells, MDA-MB 231 (ATTC, 
Manassas, USA) and SKBr-3 (ATTC, Manassas, USA) were used for cell 
culture experiments. High glucose Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % fetal calf serum and 10 % non-essential 
amino acids (NEA) was used for cultivation of the MDA-MB 231 cells. Rosewell 
Park Memorial Institute (RPMI) medium with 10 % fetal calf serum supplement 
was used for SKBr-3 cells.  For optimal growing conditions, cells were provided 
with suitable humidity along 37ºC and 7% CO2.  
2.2.2.6.1 In-vitro Cytotoxicity 
2.2.2.6.1.1   MTT Assay for Dox-MSNPs and Lip-Dox-MSNPs 
For the cytotoxicity and cellular uptake studies, in-vitro cell culture experiments 
were performed where SKBr-3 breast cancer adenocarcinoma cells were used. 
Cells were incubated overnight with RPMI medium containing 10 % fetal calf 
serum (FCS) in 96 well plate having cell density of 1x104 cells/well. After 






MSNPs containing specific concentrations of Dox for different time intervals 
including 4 hrs, 24 hrs, 48 hrs and 72 hrs. Medium was removed and fresh 
medium was added after specific time and incubated overnight. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye with a final 
concentration of 0.6 µg/ml in fresh medium was replaced with old medium and 
incubated for 4 hrs. Finally, the medium was replaced with DMSO (dimethyl 
sulfoxide) to dissolve formazan crystals and absorbance was measured at 
570 nm with plate reader (FLUOstar, BMG Labtech GmbH, Germany) to 
evaluate the viability of cells.  
The cell viability was calculated by using following formula. 
% Viability = ((AbSample – AbBlank)/(AbControl – AbBlank)) X 100% 
Where AbBlank was the absorbance of no cells while AbSample and AbControl were 
taken as treated and non-treated cells respectively. All the samples were 
measured in triplicate and results are given as average. 
2.2.2.6.1.2  MTT Assay for US Responsive Carriers 
For the cytotoxic studies and drug delivery behavior, MDA-MB 231 cells were 
seeded in 20 cm2 Petri dish (40x104 cells/cm2) in 5ml of medium and incubated 
for 24 hrs at 37ºC under 7 % CO2 atmosphere. After incubation period medium 
was removed and Lip-Dox-MSNPs, Lip-Dox-MSNPs (US), Lip-PFP-Dox-
MSNPs and Lip-PFP-Dox-MSNPs (US) having definite quantity of Dox (ranging 
from 200 µg/ml to 1.56 µg/ml) diluted in 5 ml of fresh medium were added to 
petri dishes and incubated for 4 hrs for uptake. For standard, same 
concentrations of pure Dox were also added to other petri dishes. All petri 
dishes were taken in triplicate. After incubation old medium was replaced with 
fresh medium and assigned petri dishes were subjected to ultrasound 
radiations for 5 min as shown in figure 10.  
For uniform radiation, the position of petri dish was changed and after 
ultrasound the petri dishes were incubated overnight. 3-(4,5-dimethylthiazol-2-





yl)-2,5-diphenyltetrazolium bromide (MTT) was diluted with fresh medium 
having final concentration 0.6 µg/ml and old medium was replaced with it by 
adding 5 ml to each plate and incubated for 4 hrs. After removal of medium, 
DMSO was added and mixed well, to dissolve the formazan crystals. Finally, 
the solution from each petri dish was transferred to 96 well plate in triplicate 
and absorbance was measured as mentioned in section 2.2.2.6.1.1. Whole of 
the experiments were performed in triplicate and results were calculated as an 
average along with standard deviation. 
 
Figure 10: In-vitro cell culture US irradiation for triggered release 
 
2.2.2.6.2 Cellular Uptake Pathway Analysis  
As different endocytic pathways are involved in the uptake of the same 
nanomaterials by different cell lines,120  similarly certain modifications in 
nanomaterials result in the adaptation of different pathways for the 
internalization into the same cell lines. To evaluate the internalization pathway 
of Dox-MSNPs and Lip-Dox-MSNPs cell viability assay was performed with two 
different pathway inhibitors. Chlorpromazine is responsible for the inhibition of 
clathrin dependent endocytosis along with intracellular interference of clathrin 
processes. Filipin III interacts with cholesterol and ultimately inhibit the 
caveolea endocytic pathway.121 Briefly, SKBr-3 cells were seeded to 96 well 
plates with 1x104 cells /well and incubated overnight. Cells were washed with 
PBS buffer (pH 7.4) containing Ca2+ and Mg2+ and incubated with 
chlorpromazine (6 µM) and filipin III (3 µM) diluted with fresh medium for 30 
min. After washing again with PBS buffer, cells were incubated with Dox-
MSNPs and Lip-Dox-MSNPs containing 50µg/ml of Dox for 4 hrs and then with 






for 4 hrs and absorbance of formazan crystal dissolved in DMSO was measured 
at 570 nm.   
2.2.2.6.3 Cellular Uptake Studies 
For cellular uptake studies SKBr-3 cells were seeded with RPMI medium in 6 
well plates with cell density of 25×104 cells/cm2 with coverslips. After 24 hrs 
incubation, cells were washed twice with PBS buffer. Dox-MSNPs and Lip-Dox-
MSNPs diluted with medium were added and incubated for 4 hrs. After 
incubation, cells were washed twice with PBS buffer; later 300 µl of 4 % 
paraformaldehyde was added into each well and incubated for 10 min to fix the 
cells. After aspiration 300 µl of the nucleus staining fluorescent dye 4’, 6-
diamidino-2-phenylindole (DAPI) was added and incubated for 25 min. At the 
end, cells were washed again twice with PBS buffer and coverslip was placed 
on a glass slide for imaging.  
Cellular uptake studies for US responsive drug delivery system was also 
performed where MDA-MB 231 cells were seeded with DMEM medium (cell 
density 40×104 cells/cm2) in 20 cm2 petri dish with cover slips in each well and 
incubated for 24 hrs. After incubation and washing twice with PBS buffer as 
mentioned above, Dox-MSNPs, Lip-PFP-Dox-MSNPs (US) and Lip-Dox-
MSNPs diluted with medium were added to wells and incubated for 4 hrs. After 
removing, the old one, new medium was added to give US radiations for 5 min 
to Lip-PFP-Dox-MSNPs (US). Later on for washing, fixing, staining with DAPI 
and preparation of slides, same procedure was adopted as mentioned above.  
The cell images were taken by using confocal laser scanning microscope 
(Zeiss, LSM 510, Germany). DAPI was excited by UV laser at 364 nm and 
emission was detected at 385-470 nm. Similarly, Dox was excited at 480 nm 
and FITC was excited at 495 nm. The emissions of Dox and FITC were detected 
at 560-590 nm and 519 nm respectively.122 
 





2.2.2.7 Cell Culture Experiments under Hypoxia 
In-vitro cell culture experiments under hypoxic conditions were also performed 
with MDA-MB 231 cells. Same medium, as mentioned above was used for cell 
culturing. Cells were maintained under hypoxic conditions in SciTive Hypoxic 
Workstation (Baker Ruskinn, Leads, UK) with1 % O2, 5% CO2 and residual N2. 
For comparison, cells were grown in normoxic conditions with 7 % CO2 and 
residual N2. 
2.2.2.7.1 Extracellular Acidification Test 
As over expression of CA-IX under hypoxic conditions results in extracellular 
acidic environment. To investigate the effects of drug delivery system extra 
cellular acidification test was performed before and after exposure to 
formulations under hypoxia and normoxia. Cells were seeded in 6 well plates 
and incubated in hypoxic and normoxic conditions for 24 hrs. Later on, cells 
were incubated with different formulations diluted with medium for 24 hrs. The 
pH of each well was measured before and after treatment. 
2.2.2.7.2 Immunoblotting 
The over expression of CA-IX enzyme in hypoxic conditions was validated. 
Cells were seeded in 6 well plates with density of 25 X 104 cells/cm2 and 
maintained under hypoxic and normoxic conditions for 24 hrs. Afterwards, 
media was removed and cells were washed wit PBS buffer. Later on cells were 
harvested and pellet was obtained, subsequently lysed with lysis buffer 
containing (4% SDS, 100mLTris/HCl and 150mM NaCl, pH 7.4) and stored at -
20ºC. After determining total protein concentration with protein assay kit (Bio-
Rad, Munich, Germany), western blot was performed for evaluation of CA-IX 
and HIF-1α expression. Briefly, 50µg of protein was loaded to 10% SDS gel 
and blotted with Trans Blot Turbo blotting system (Bio-Rad). Membrane was 
blocked with 5% milk in TBS-T for tubulin (sigma). For CA-IX (H-11) monoclonal 
antibody was used as primary antibody against CA-IX enzyme. 123,124 Similar 






CA-IX inhibitor, Lipc and  Lipc-Dox-MSNPs to assess the inhibition of CA-IX with 
24 hrs incubation time.  
2.2.2.7.3 In-Vitro Cytotoxicity (MTT Assay)  
To evaluate the in-vitro cytotoxic effects of Lipc-Dox-MSNPs cell viability assay 
was performed under hypoxic conditions. Briefly, MDA-MB 231 cells were 
seeded in 96 well plates and incubated overnight under normoxic and hypoxic 
conditions. The next day, after medium aspiration, formulations dissolved in 
medium were added. Cells were incubated for 4 hrs and 24 hrs, followed by 
same procedure for MTT assay under hypoxic and normoxic conditions, as 
mentioned in section 2.2.2.6.1.1. The amount of Dox used in each sample was 
100 µg/ml and molarity of CA-IX inhibitor was 360 nM which is higher than 
minimum effective concentration of CA-IX inhibitor (Ki=0.9 M). Finally, the 
absorbance was measured with plate reader (FLUOstar, BMG Labtech GmbH, 
Germany) at 570 nm to evaluate the viability of cells. 
  





Characterization Technique used   
Size distribution 
Dynamic Light Scattering125   
Atomic Force Microscopy126   
Transmission Electron Microscopy127   
Surfactant removal 
Elemental analysis128   
Dynamic Light Scattering   
Fourier Transform Infrared spectroscopy129   
Morphological studies 
Transmission Electron Microscopy   
Cryogenic Transmission Electron Microscopy130   
Scanning Transmission Electron Microscopy131   
Lipid Coating 
Transmission Electron Microscopy   
Cryogenic Transmission Electron Microscopy   
Atomic Force Microscopy   
Surface area, pore size 









Ultrasound contrast eZono 3000134   
Cytotoxicity  MTT assay135   
Cellular uptake Confocal Laser Scanning Microscopy136   
CA-IX expression Western blot analysis137   
 











3  Results & Discussion 






3.1 Fabrication of MSNPs and Characterization 
3.1.1 Fabrication of MSNPs 
MSNPs were prepared by a two-step sol-gel method involving hydrolysis and 
condensation as shown in figure 11. TEOS undergoes hydrolysis to form silanol 
and later condensation and polymerization between silanol-ethoxy groups or 
solanol-silanol result in formation of siloxane bridge which builds up entire silica 
structure.138  
TEOS has an isoelectric point (IEP=pH 2) and exist as a negative charge in 
basic pH. This negatively charged silica source can interact with positively 
charged moieties such as cationic surfactants. Contrarily TEOS exists as a 
positive charge in pH<2 where it can interact with anionic surfactants. Here in 
we have adopted cationic surfactant and basic environment. 
 
Figure 11: Two step hydrolysis and condensation method 
 
The size of MSNPs depends upon different factors including CTAB/TEOS ratios 
and pH of the medium. The pH of the solution directly effects the charge density 
of silica source which ultimately controls the silane hydrolysis and siloxane 
condensation rates.139 We have used five different molar mass ratios where the 
amount of CTAB was changed but TEOS amount was fixed to 2.25 mmoles. 
For the basic catalytic reactions different bases like NaOH, TEA and NaHCO3 
were used and details are shown in table 2. For the optimization of required 
size different formulations were successfully prepared and they were initially 
characterized for size and surface charge. 
  








Components n (mmol) Mass (mg) 
0.58 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 1.3 473.5 
H2O 2668 48000 
0.5 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 1.12 408 
H2O 2668 48000 
0.4 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 0.9 326 
H2O 2668 48000 
0.3 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 0.67 245 
H2O 2668 48000 
0.2 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 0.45 163 
H2O 2668 48000 
0.12 
NaOH/TEA/NaHCO3 0.7/0.56/0.7 28/83.5/58.8 
CTAB 0.27 98 
H2O 2668 48000 
 
Table 2: Different molar mass ratios (CTAB/TEOS) with different bases (NaOH, TEA, NaHCO3) 
 
  





3.1.2 Hydrodynamic Size and Surface Charge 
The size of nanomaterials is most critical factor for their applications in 
nanomedicine. The size and surface charge of particles were characterized with 
DLS and LDV and results are shown in table 3. MSNPs of different sizes, 
ranging from 50 nm to 250 nm were prepared. The results show that using 
different molar mass ratios of CTAB/TEOS with different pH solutions, different 
size MNSPs can be produced.  
The decrease of particle size by increasing the CTAB/TEOS was reported. 
Similar pattern starting from 0.2 to 0.5 molar ratio can be seen in our results 
with TEA or NaOH as shown in figure 12. It was found that molar mass ratio 
less than 0.1 was resulted in aggregation. This effect could be due to 
hydrophobic interaction between surfactants which were not part of 
mesostructured and adsorbed on particle surface in the form of monolayer with 
hydrophobic chain exposed to solution. On the other hand, the higher 
CTAB/TEOS ratios can produce uniformly dispersed MSNPs due to adsorption 
of surfactant micelles on the particle causing electrostatic repulsion.115 
The pH value also effects the size of the particles. The pH values for the final 
solution of NaOH, TEA and NaHCO3 were 11, 9 and 7.8 respectively. As the 
fabrication of MSNPs is based upon hydrolysis and condensation of TEOS and 
by increasing pH the hydrolysis can occur at faster rate. As a result, reduction 
in size was observed with increase in pH. The particle sizes of the same molar 
ratios with TEA were slightly higher than the sizes with NaOH.  
In case of NaHCO3 no significant effects in size were observed with different 
CTAB/TEOS ratios. NaHCO3 can produce very slightly basic environment, 
which is very close to neutral pH. As mentioned above, the hydrolysis and 
condensation reactions are dependent on the pH of environmental solution and 
pH close to neutral pH does not have significant effects, resulting in very slow 
or negligible hydrolysis of TEOS. 
  







Size and                       
Surface Charge 
NaOH TEA NaHCO3 
0.58 
Size ± SD [nm] 81.31 ± 3.11 90.29 ± 5.45 72.45 ± 0.29 
PDI 0.32 0.46 0.11 
Zet. Pot ± SD [mV] 41.10 ± 2.97 35.90 ± 0.72 41.80 ± 1.16 
0.5 
Size ± SD [nm] 69.85 ± 2.08 74.53 ± 5.42 70.86 ± 0.16 
PDI 0.27 0.39 0.05 
Zet. Pot ± SD [mV] 32.30 ± 0.32 21 ± 2.80 47 ± 1.78 
0.4 
Size ± SD [nm] 102.70 ± 2.04 108.70  ± 33.90 70.61 ± 0.444 
PDI 0.54 0.29 0.16 
Zet. Pot ± SD [mV] 32.60  ± 1.13 22 ± 0.29 38.70 ± 1.44 
0.3 
Size ± SD [nm] 115.70 ± 1.13 131.80 ± 10.88 79.3 ± 0.62 
PDI 0.21 0.27 0.21 
Zet. Pot ± SD [mV] 29.60  ± 4.30 22.20 ± 0.78 31.30 ± 0.98 
0.2 
Size ± SD [nm] 197.10 ± 3.10 232 ± 28.18 78.57 ± 0.21 
PDI 0.24 0.53 0.27 
Zet. Pot ± SD [mV] 34  ± 0.62 20.90 ± 0.22 27.50 ± 1.56 
0.12 
Size ± SD [nm] 
Aggregation 
44.65 ± 3.46 87.35 ± 0.65 
PDI 0.16 0.20 
Zet. Pot ± SD [mV] 12.10 ± 1.73 23.50 ± 1.26 
 
Table 3: Size distribution with PDI along with surface charge of different molar mass ratios 
(CTAB/TEOS) with different bases (NaOH, TEA, NaHCO3) 
 
Our results are indicating that the size of MSNPs depends not only upon 
CTAB/TEOS ratios but to some extent on the pH of environmental solution. 
Higher the molar mass ratio of CTAB/TEOS lower would be the size of MSNPs. 
Contrarily in inverse relation between size of MSNPs and pH up to certain level 
was observed which is consistent to previous findings.140 So, the pH and 
CTAB/TEOS ratios in specific range are necessary to produce stable MSNPs. 






Figure 12: Graph showing size distribution and surface charge of different CTAB/TEOS ratios 
with different bases (NaOH, TEA, NaHCO3) 
 
3.1.3 Elemental Analysis 
After fabrication of MSNPs next step was the removal of surfactant template for 
the generation of porous structure. Here in we have adopted ethanolic 
extraction in acidic environment. The MSNPs were extracted for different time 
intervals for optimal surfactant removal. All of these samples were later 
characterized for elemental analysis and results are shown in table 4. As a 
comparison, MSNPs with surfactant template were also analysed. Here a sharp 
decrease in N2, C, H and Br % ages was observed just after 5 min of extraction. 
So we can assume that 5 min of extraction was able to remove most of the 
surfactant but traces of these elements are indicating the presence of surfactant 
inside pores. A very slow decrease in % age of N2, C and Br was observed from 
5 min to 5 hrs. On the other hand, the % age reduction of H was very slow from 
0 min to 5 hrs. This slower reduction could be due to availability of some of the 
water traces in the sample but it has reached to minimum after 2 to 3 hrs. 






Nitrogen (%)           
± SD  
Carbon (%)              
± SD  
Hydrogen (%)              
± SD  
Bromine (%)           
± SD  










5min 0.27 ± 0.02 8.83 ± 0.13 6.99 ± 0.06 3.56 ± 0.37 
10min 0.26 ± 0.01 8.19 ± 0.07 3.13 ± 0.09 3.66 ± 0.16 
15min 0.27 ± 0.01 8.81 ± 0.05 3.03 ± 0.04 3.53 ± 0.39 
20min 0.27 ± 0.02 8.52 ± 0.06 2.99 ± 0.03 5.58 ± 0.21 
30min 0.29  ± 0.02 8.08 ± 0.13 2.92 ± 0.01 5.35 ± 0.10 
40min 0.29 ± 0.02 8.25 ± 0.11 2.80 ± 0.01 3.84 ± 0.01 
50min 0.29 ± 0.02 7.10 ± 0.01 2.90 ± 0.07 3.35 ± 0.02 
1hr 0.10 ± 0.04 5.44 ± 2.40 2.06 ± 0.66 3.60 ± 0.30 
2hr 0.10 ± 0.01 3.92 ± 0.18 1.75 ± 0.01 4.59 ± 1.71 
3hr 0.09 ± 0.03 3.90 ± 0.25 1.83 ± 0.30 3.89 ± 0.69 
4hr 0.06 ± 0.03 4.04 ± 0.07 2.02 ± 0.21 3.66 ± 0.63 
5hr 0.06 ± 0.01 3.49 ± 0.17 1.78 ± 0.04 3.74 ± 0.37 
6hr 0.09 ± 0.01 3.66 ± 0.35 1.98 ± 0.04 3.94 ± 1.10 
7hr 0.10 ± 0.04 3.79 ± 0.19 1.69 ± 0.16 3.94 ± 0.22 
8hr 0.08 ± 0.01 4.20 ± 0.24 1.81 ± 0.04 4.20 ± 0.50 
23hr 0.08 ± 0.03 4.20 ± 0.17 1.90 ± 0.09 3.88 ± 0.02 
24hr 0.07 ± 0.01 4.10 ± 0.38 1.82 ± 0.18 4.02 ± 0.23 
 
Table 4: Percentages by weights of nitrogen, carbon, hydrogen and bromine in MSNPs after 
different extraction times. 
 
3.1.4 Nitrogen Sorption Analysis (BET) 
The role of extraction in surfactant removal was assessed with nitrogen sorption 
analysis because the surface area and porous structure was directly linked with 
availability of surfactant in pores. We have characterized same samples with 
different extraction times as we have analysed for elemental analysis. The 
results of different samples in terms of their surface area, volume, pore 
diameter and total pore volume are shown in table 5, where surface area and 
volume were obtained from BET while pore diameter and total pore volume 





were obtained from BJH method.  Here we can observe that MSNPs (surf) 
without washing has not shown larger surface area due to the fact of available 
surfactant template in pores with very low volume but after extraction this 
surfactant was removed and an increase in surface area was observed. Here, 
even after 5 min of extraction a larger surface area was created which is above 
800 cm2/g with volume of 191.25 cm3/g at standard temperature and pressure 
(STP). The pore size of 2.43 nm in diameter with 0.84 cm3/g also indicates the 
removal of surfactant. We have observed that with increasing extraction time 
the surface area and volume have been increased but the pore diameter 
remained the same for all the samples. As the data shows the maximum of the 
surface area and surface volume were attained with 6 hrs of extraction which 
are 1134 cm2/g and 260.61 cm3/g at STP respectively and corresponding total 
pore volume was 1.072 cm3/g.  
Afterward a decreasing trend was observed in surface area and volume where 
7 hrs and 8 hrs extractions have shown small reduction but later on a significant 
reduction was observed. This significant difference might be due to the longer 
time extraction of MSNPs in acidic ethanol, which resulted in abrasion of 
particles at edges. This damage of the MSNPs has reduced the surface areas 
and volumes significantly, but the pore size remained the same however, the 
total pore volumes have been kept on reducing. These findings show that 
optimal extraction time is also very important for the surfactant removal without 
damaging the structure of MSNPs. By our results, we can assume that 6 hrs 
extraction time141 is optimal duration for surfactant removal and these MSNPs 
were further used for other experiments. 
The nitrogen adsorption-desorption isotherm of MSNPs with 6 hrs extraction 
time is shown in figure 13. Insight is the pore diameter measured with BJH 
method. Here it can be observed that adsorption-desorption isotherm is similar 
to type-IV isotherm with hysteresis loop where lower branch is representing 
addition of adsorption gas while upper branch represents withdrawal of the gas. 
This specific shape of hysteresis loop is directly associated with capillary 
condensation in the filling and emptying of mesoporous structures. These 





results are clearly indicating mesoporous nature of our carriers and these 
finding are similar to Seyyed et. al.142 
Samples 
Surface Area  
(m2/g) 




Total Pore Vol  
(cm3/g) 










5min 832.30 191.25  2.43 0.84 
10min 845.00 194.16  2.43 0.87 
15min 924.10 212.33  2.43 0.96 
20min 969.60 222.76  2.43 0.82 
30min 939.40 169.88  2.43 0.72 
40min 950.30 218.34  2.43 0.98 
50min 964.35 159.53  2.43 0.75 
1hr 984.60 230.81  2.43  0.81 
2hr 995.38 228.69  2.43 0.67 
3hr 918.25 210.97  2.43 0.60 
4hr 909.60 208.99  2.43 0.62 
5hr 1084.40 249.14  2.43 0.75 
6hr 1134.43 260.61  2.43 1.07 
7hr 1121.10 211.63  2.43 0.73 
8hr 1098.20 252.31  2.43 0.61 
20hr 902.70 238.48  2.43 0.81 
23hr 932.57 214.26  2.43 0.66 
24hr 913.52 209.88  2.43 0.65 
 
Table 5: Surface area, surface volume, pore size and total pore volume of MSNPs after different 
extraction times. 
 






Figure 13: Nitrogen Adsorption-desorption isotherm with pore size of MSNPs after extraction.  
 
3.1.5 Fourier Transform Infrared (FTIR) Spectroscopy 
The development of MSNPs and removal of surfactant was characterized by 
FTIR and results are shown in figure 14. CTAB surfactant typically showed two 
intense peaks in the region of 2800-3200 cm-1 which are corresponding to 
symmetric (2850 cm-1) and asymmetric (2915 cm-1) stretching vibrations of CH2 
chains. The presence of these specific peaks in spectrum of CTAB-MSNPs 
shows the availability of surfactant template in pores, which was later removed 
with extraction. In case of extracted MSNPs, the absence of these CTAB peaks 
indicates the removal of surfactant.143,144 
On the other hand, FTIR spectrum of CTAB-MSNPs showed that a broad band 
in the region of 1000-1300 cm-1 is characteristic feature of Si-O-Si. The peaks 
at 1042 cm-1 and 953 cm-1 are typically for asymmetric vibrations of Si-O-Si and 
Si-OH respectively. The signals at 796 cm-1 are attributed to symmetrical 
stretching of Si-O-Si vibrations and signals at 440 cm-1 are due to bending 
vibrations of Si-O-Si. Our findings are in accordance to already reported data.145 





FTIR Spectrum is not only showing the surfactant removal but also the 
formation of silica structure. 
 
Figure 14: FTIR spectrums of CTAB, CTAB-MSNPs and MSNPs  
 





3.1.6 Morphological Studies 
3.1.6.1 Atomic Force Microscopy (AFM) 
For the initial characterization of morphology and size distribution, AFM 
investigations were performed. Although we were unable to visualize the 
porous structure of MSNPs but AFM images can help to realize the real size 
distribution. Figure 15 A is amplitude trace image of MSNPs where we can 
observe that MNSPs are well dispersed with no significant aggregation. The 
particle size was less than 100 nm which corresponds to the size distribution 
characterized with dynamic light scattering. Most of MSNPS were completely 
round in shape however, few elongated MSNPs can also be observed. Figure 
15 B and 15 C are amplitude phase and 3D height traced micrographs of a 
single particle respectively where the shape of the particles can be visualized. 
We can see that particles are not completely round in shape but a little bit 
elongated which is in accordance to the already reported shape of MSNPs.146 
The morphology of MSNPs indicates that hexagonal array was extended more 
to one direction than others. 
 
Figure 15: AFM micrographs of (A & B) amplitude trace and (C) height trace of MSNPs  
 
3.1.6.2 Transmission Electron Microscopy (TEM) 
Morphological studies of MSNPs were performed with TEM and results are 
shown in figure 16. MSNPs were visualized before and after surfactant removal. 
Here the figures 16 A, 16 B and 16 C are showing the images of MSNPs with 
surfactants. Although the porous structure was not visualized because of 
presence of surfactant template but light and dark contrast could be due to 





CTAB and TEOS. We can observe that particle size is less than 100 nm which 
is similar to that measured by DLS. Few of the MSNPS were not completely 
round as in figure 16 B, where face to face attachment is showing that few of 
MSNPs are of hexagonal shape with round edges due to porous hexagonal 
array which extended to the edges of the MSNPs. The dark spots around the 
particles in figure 16 B and C, are in the range of 2nm which might be the round 
micelles of CTAB. On the other hand, we can observe the porous structure of 
MSNPs after extraction of surfactant as shown in figure 16 D and E. The pore 
size was in the range of 2-3 nm, which corresponds to BJH pore size 
measurement. A uniform hexagonal porous structure can be observed in figure 
16 E, where insights of image E (i & ii) are showing Fast Fourier Transform 
(FFT) and Inverse Fast Fourier Transform (IFFT) respectively. This FFT and 
IFFT patterns are clearly indicating hexagonal structure and further confirm the 
porosity of MSNPs.   
 
Figure 16: TEM images of MSNPs (A-C) with surfactant and (D&E) without surfactant where 
E(i) & E(ii) are representing FFT and IFFT patterns respectively  





3.1.6.3 Scanning Transmission Electron Microscopy (STEM) 
The structural morphology of MSNPs was further confirmed with STEM. The 
dark field images were taken and micrographs are represented as figure 17. 
The size distribution in figure A shows that the MSNPs were in the range of 50-
100 nm. These findings are similar to already reported data.131,147 Figure 17 B 
shows MSNP with ordered 2D hexagonal porous structure with closely packed 
porous array. The shape of MSNPs was round to hexagonal with round edges. 
The pore size was almost 2-3 nm, which is similar to the results found by BJH 
pore measurement and by TEM images.  
 
 
Figure 17: STEM micrographs showing shape and porous structure of MSNPs 
 
3.1.7 UV-Visible Spectrophotometer 
The absorption spectrum of DOX was measured with UV-visible 
spectrophotometer in the range of 300-700 nm. The results showed that 
maximum absorption peak of Dox was at 495 nm and 482 nm when dissolved 
in water and PBS buffer (pH 7.4) respectively. Different concentrations of Dox 
were prepared in water and buffer ranging from 1 µg/ml to 25 µg/ml and 
absorbance for each concentration was measured on corresponding 
wavelength. The absorbance value as a mean of triplicate was calculated and 





results are presented in graphs as shown in figure 18. The drug entrapment 
and release profile were measured with the help of these calibration curves. 
 
Figure 18: Calibration curves of Dox dissolved in (A) water and (B) PBS 7.4 pH. 






3.2 Lipid Coated MSNPs as a Drug Delivery System 
3.2.1 Liposome Preparation 
Protocells in the form of liposomes were developed by thin layer hydration 
method, previously adopted by our research group. Different lipids were used 
in different molar percentages and finally DPPC, DOTAP and cholesterol with 
molar ratio of 85:3:12 were selected as a carrier for coating the MSNPs surface 
due to their relatively non-toxic effects. Another reason was higher blood 
compatibility in intravenous application with lower toxicity of lipid to cell 
membranes due to structural nature and resemblance for enhanced cellular 
uptake which has already been defined in previous reports.48,49 
3.2.2 Lipid Coating of MSNPs 
To optimize uniform lipid coating on the surface of MSNPs, different mass ratios 
of MSNPs to liposomes were used. Due to solid rigid structure, MSNPs were 
able to be entrapped within the softer liposomal structure due to shear applied 
by pipetting and vortex mixing. Selection of cationic lipid was based on the 
concept to develop a counter charge moiety on the surface of anionic silica for 
uniform coating. Apart from this, the surface tension of the liposomes has also 
a critical role in coating of the lipid layer on MSNPs surface. The logic behind 
the coating of MSNPs with lipid was to integrate the gatekeeping effect to pore 
opening to avoid premature leakage of the drug and to sustain the release of 
drug through lipid layer.47,75  
3.2.3 Characterization 
3.2.3.1 Dynamic Light Scattering (DLS) 
MSNPs were initially characterized by dynamic light scattering (DLS) for size 
distribution and for surface charge where the particle size was in the range of 
118.30 ± 2.42 nm with PDI 0.16, indicating monodisperse but broad size 
distribution as shown in table 6. The size distribution curve is shown in 





figure 19, demonstrating particle sizes between 50 nm and 300 nm with a mode 
at around 100 nm. By washing MSNPs the surfactant was removed from the 
pores and it was confirmed by the shift of surface charge from 
+33.60 ± 4.67 mV to -17.03 ± 3.50 mV by Laser Doppler Velocimetry. Size 
distribution of MSNPs along with PDI and zeta potential are shown in table 6 
and figure 19.  
 
Figure 19: DLS measurements for Size distribution of (A) MSNPs (B) Liposomes and (C) Lip-
MSNPs. 
 
Liposomes obtained by above mentioned method were also characterized by 
DLS where the measured size and zeta potential was 126.13 ± 11.77 nm and 
+18.16 ± 3.50 mV respectively with 0.18 PDI as in table 6. Figure 18 also shows 
the size distribution curve.  
  
Particle size ± 
SD [nm] 
PDI 
Zeta Potential ± 
SD [mV] 
  
MSNPs 118.30 ± 2.42 0.16  +33.60 ± 4.67 Before washing 
       -17.03 ± 3.50 After washing 
Liposomes 126.13 ± 11.77 0.18 +18.20 ± 3.50   
Lip-MSNPs 129.90 ± 10.40 0.24  +7.86 ± 2.90   
 
Table 6: Particle size, polydispersibility index (PDI) and zeta potential of MSNPs by DLS and 
LDV. 
 
DLS measurements have shown that by coating of the lipid on MSNPs, the size 
has been increased to 129.90 ± 10.40 nm which is almost 12 nm higher than 
MSNPs. Lipid coating on the surface of MSNPs resulted in a shift of charge 





from negative (MSNPs) to positive side due to cationic nature of liposome. A 
shift of charge from -17.03 ± 3.50 mV to +7.86 ± 2.90 mV is also an indication 
of lipid coating as shown in table 6. 
3.2.3.2 FTIR of Lipid Coating 
The lipid coating of MSNPs was further ascertained with FTIR spectroscopy 
and results are presented in figure 20. The IR spectrum of liposomes with 
characteristic peaks in range of 2800-3000 cm-1 indicates the presence of 
hydrocarbons. The characteristic peaks at 2850 cm-1 and 2915 cm-1 are 
showing symmetric and antisymmetric stretching of CH2 group of alkyl chain 
respectively. The peak at 1734 cm-1 is characteristic feature of ester carbonyl 
group of DPPC lipid.148 On the other side the characteristic peak at 1058 cm-1 
for MSNPs is due to asymmetric vibration of Si-O-Si groups. After lipid coating 
to MSNPs, similar peaks were identified which shows the lipid coating of 
MSNPs. This kind of IR spectrum of lipid coated MSNPs is already reported 
and our results are in accordance to those findings.149  






Figure 20: FTIR spectrums of MSNPs, Liposomes and Lip-MSNPs  
 





3.2.3.3 Morphological Studies with TEM and Cryo-TEM 
The Cryo-TEM was performed to visualize the physical state of liposomes along 
with lipid coating to MSNPs. Liposomal size confirmed by CryoTEM images 
was in the range of 80-120 nm which is similar to the Z-average diameter 
measured by DLS as can be seen in figure 21 A. The liposomes are round in 
shape and images further confirmed the unilamelar character of the vesicles. 
As it was assumed that positively charged liposomes could be coated to 
negatively charged MSNPs. Figure 21 B is cryo-TEM micrograph of lipid coated 
MSNPs where a clear lipid bilayer uniform structure can be seen around 
MSNPs. The size of lipid layer was around 7-8 nm which is almost similar as in 
figure 21 A. An increase in MSNPs size from 110 nm to 130 nm was observed 
with lipid coating and these findings are similar to DLS size distribution. Based 
on literature and comparing with our findings it was established that lipid was 
successfully coated to MSNPs.150 For further confirmation of lipid layer bound 
to MSNPs TEM micrographs were also obtained. Here negatively stained 
sample with 2 % uranyl acetate were visualized by TEM for good contrast as 
shown in figure 21 C. The thickness of outer layer shows a uniform lipid coating 




Figure 21: Cryo-TEM images of (A) liposomes with scale bar 100 nm (B) Lip-MSNPs with scale 
bar 50 nm and (C) TEM image of Lip-MSNPs negatively stained with 2 % uranyl acetate with 
scale bar 10 nm. 
  





3.2.4 Drug Loading 
Drug loading capacity of MSNPs was investigated by using cytostatic agent 
Dox as a tumor therapeutic agent. We have taken different amounts of Dox with 
2.5 mg of MSNPs as mentioned in table 7. Here we have observed that the 
drug loading in each case was around 50 %. We can assume that due to high 
surface area, MSNPs have tendency to entrap large amount of drug50,118,151 and 
in our studies Dox to MSNPs ratio was 1.2 mg/mg. Dox due to amine group in 
its structure has overall positive charge and MSNPs due to silica exhibits 
negative charge. Because of electrostatic interaction between Dox and MSNPs, 
Dox can be easily entrapped in MSNPs.152 The high loading capacity is due to 
availability of large surface area of porous structure.47 Our results have shown 












1.5 2.5 0.6 0.757 50.4 
3 2.5 1.2 1.275 42.0 
6 2.5 2.4 2.940 48.4 
12 2.5 4.8 5.840 48.6 
 
Table 7:  MSNPs drug loading capacity and % age entrapment efficacy 
 
3.2.5 In-vitro Drug Release 
In-vitro Dox release studies were performed to evaluate the release pattern. 
Here we have observed that the release of Dox from MSNPs was very slow as 
shown in figure 22. This sustained release behaviour of MSNPs made them 
suitable candidate for the delivery of chemotherapeutic drug after reaching to 
target site and to produce the anticancer effects for longer duration. Our data 
shows that % age amount of Dox release was about 7% even after 24 hrs. 
These findings are in accordance to Gao et. al, where a very sustained release 





effect of drug at neutral pH has been reported.118 We have observed from the 
release profile that Dox release rate from Lip-Dox-MSNPs was slower than from 
bared MSNPs. This relative slower release of Dox from Lip-Dox-MSNPs was 
due to more retention by lipid coating which prevented the release of drug. The 
lipid layer due to its hydrophobic nature can reduce the permeability of 
hydrophilic drug as a result of which lesser amount of drug release was 
observed. The sustained release effect due to lipid coting to MSNPs has 
already been reported.75 
 
Figure 22: Doxorubicin release profile from Dox-MSNPs and Lip-Dox-MSNPs 
 
3.2.6 Drug Leakage Test 
To evaluate the gatekeeping effect of lipid layer for Lip-Dox-MSNPs, drug 
leakage test was performed. The purpose of this test was to study the stability 
of drug delivery system under inert conditions. The results are shown in 
figure 23, where we can observe that the release of Dox from Dox-MSNPs was 
faster as compared to Lip-Dox-MSNPs. The amount of drug released after 10 
days from Lip-Dox-MSNPs was around 6 % whereas in case of Dox-MSNPs it 





was about 20 %. This faster release from Dox-MSNPs is due to absence of lipid 
layer which is playing a role as a gatekeeper to the pore opening. These 
findings are in accordance to the literature where drug leakage was minimized 
by lipid coating to MSNPs.47 These results are in support to our assumption for 
the lipid coating to avoid or reduce premature leakage of the drug. 
 
 
Figure 23: Drug leakge profile showing the release of drug from Dox-MSNPs and Lip-Dox-
MSNPs under inert condition 
. 
3.2.7 Cell Culture Experiments 
3.2.7.1 In-Vitro Cytotoxicity (MTT Assay) 
To evaluate cytotoxic behaviour of drug delivery system, cell viability assay was 
performed with MTT assay. Initially blank carriers were evaluated for their 
biocompatibility and inertness. The same procedure was adopted as used for 
drug loaded carriers. It was observed that both MSNPs and Lip-MSNPs were 
non-cytotoxic in nature as shown in figure 24. Here we have used just 4 hr 
incubation time with MSNPs and Lip-Dox-MSNPs. After evaluation of inertness 
of blank carriers, the study was extended to drug loaded carriers for longer 
incubation periods. 
 






Figure 24: Cell viability of blank MSNPs and  Lip-MSNPs 
 
 
The findings of cell viability assay have shown that after 4 hrs of incubation, 
Dox-MSNPs resulted in more toxicity to the cells as compared to Lip-Dox-
MSNPs. But after 24 hrs, 48 hrs and 72 hrs of incubation the results were 
inverted and Lip-Dox-MSNPs have shown increased toxicity compared to Dox-
MSNPs carriers as can be seen in Figure 25. The higher toxicity of Dox-MSNPs 
after 4 hrs incubation might be due to the relatively faster release of Dox from 
MSNPs as there was no lipid coating. On the other hand, even after higher 
cellular uptake of Lip-Dox-MSNPs due to lipid coating, lesser toxicity was 
observed due to the sustained release effect of lipid layer at the pore opening 
which hindered the release of drug. After 24 hrs of incubation the cytotoxicity 
by Lip-Dox-MSNPs was increased as compared to Dox-MSNPs and these 
effects are due to higher amount of drug uptake by the cells due to 
biocompatibility of lipid layer. Once the higher amount of carrier was available 
in the cells it required some time to release higher concentration of Dox as 
compared to Dox-MSNPs to cause more toxicity. Similar pattern of toxicity was 





observed after 48 hrs and 72 hrs of incubation. Our cytotoxic studies have 
shown toxicity, which was not only concentration but time dependent as well.  
 
Figure 25: In-vitro cytotoxicity evaluation by MTT assay with SKBR-3 breast cancer cells after 
(A) 4 hrs, (B) 24 hrs, (C) 48 hrs and (D) 72 hrs incubation of Dox-MSNPs, Lip-Dox-MSNPs and 
Dox. Data is presented as mean ± SD (n=3) 
 
3.2.7.2 Pathway Uptake Analysis 
The results of cellular uptake pathway studies are given in figure 26 which 
indicates that Dox-MSNPs with filipin III has shown no difference in cell viability 
but with chlorpromazine significant effects were observed. So we can say that 
Dox-MSNPs were internalized by clathrin mediated endocytosis and not by 
caveolea/lipid-raft mediated. In comparison, Lip-Dox-MSNPs with 
chlorpromazine and filipin III have shown higher cell viability, indicating 
involvement of both clathrin mediated and caveolea/lipid-raft mediated 
endocytosis. Effects of pure Dox suggest the adaptation of some other 





mechanisms instead of both above mentioned pathways. These findings 
indicate that the internalization of Lip-Dox-MSNPs utilizes not only clathrin 
mediated but caveolea endocytosis pathway which is advantageous to Dox-
MSNPs clathrin mediated endocytosis. 
 
Figure 26: Cellular uptake pathway analysis: where MTT assay of SKBR-3 cells was performed 
after 30min incubation of two different pathway inhinitors including chlorpromazine (6 µM) and 
filipin III (3 µM) with Dox-MSNPs, Lip-Dox-MSNPs and Dox. 
 
3.2.7.3 Cellular Uptake Studies 
Dox, a fluorescent moiety, interacts with DNA and tends to be internalized into 
the nucleus. To confirm the localization of Dox in nucleus of the cells, qualitative 
fluorescence imaging with CLSM was performed.122 Cells were incubated with 
Dox-MSNPs and Lip-Dox-MSNPs containing 12.5 µg/ml of Dox for 4 hrs and 
after staining nucleus with DAPI, cells were fixed to glass coverslip and 
observed under CLSM. The microscopic images are shown in figure 27 where 
the localization of Dox was observed in the nuclear region along with DAPI. As 
postulated, stronger red intensity indicates the higher internalization of the Dox 
by Lip-Dox-MSNPs as compared to Dox-MSNPs. It is obvious that the higher 
internalization of Lip-Dox-MSNPs was due to more biocompatible protocell 
nature of lipid layer which enhanced cellular uptake. Although the Dox intensity 
of Dox-MSNPs is also indicating the delivery of drug to target site but as our 





aim was to deliver the drug in higher concentrations, so Lip-Dox-MSPs were 
able to accomplish it. Apart from localization of Dox in the nuclear region for 
Lip-Dox-MSNPs, we can observe the higher intensity outside the nucleus as 
well. This might be due to the availability of the drug which was not completely 
released due to lipid layer and may require some time to get released and 
internalized in nucleus. These findings are supportive to our MTT assay results 
where after 4 hrs of incubation Dox-MSNPs have shown bit higher toxicity as 
compared to Lip-Dox-MSNPs and this higher toxicity would be due to relative 
faster release in the absence of lipid layer. Although the lipid layer has 
increased the cellular uptake but released the drug in a sustained manner which 
is also evident from 24 hrs, 48 hrs and 72 hrs toxicity results where Lip-Dox-
MSNPs have shown significantly higher toxic effects to the cells. 
 
Figure 27: CLSM images after uptake of Dox-MSNPs and Lip-Dox-MSNPs by SKBR-3 cells 
where blue and red fluorescence in the nuclear region correspond to DAPI and Dox along with 
merged images. Higher cellular uptake of Lip-Dox-MSNPs can be visualized by higher 
























3.3 Ultrasound Triggered Release Lipid Coated MSNPs 
3.3.1 Surface Modification and Characterization 
MSNPs after surface modification were characterized with FTIR spectrum and 
results are shown in figure 28. In comparison to unmodified MSNPs, surface 
modified MSNPs have shown few new characteristic FTIR peaks. These peaks 
are at 3354 cm-1 and 1631 cm-1 which are indicating asymmetrical NH2 
bending, which confirmed the NH2 group existence. Although peak at 3354 cm-
1 is not very prominent because of the OH and NH2 group spectrum overlap. It 
is evident from literature that such kinds of results have been observed after 
surface modification of MSNPs.153,154 
 
Figure 28: FTIR spectrums of MSNPs and surface modified NH2-MSNPs  





Surface modification was further confirmed by surface area measurements with 
N2 adsorption-desorption technique where reduction in surface area and 
surface volume has been observed as shown in table 8. Although the pore size 
remained unchanged but total pore volume was reduced. 
Samples 
Surface Area  
(m2/g) 




Total Pore Vol  
(cm3/g) 
MSNPs 1134.43 260.61  2.43 1.07 
NH2-MSNPs 935.88 215.02  2.43 1.01 
 
Table 8: Surface area and surface volume of MSNPs and modified NH2-MSNPs 
 
3.3.2 Preparation of Lip-PFP-Dox-MSNPs 
Dox loaded MSNPS were prepared as mentioned in section 2.2.1.5. After 
complete washing, lyophilized Dox-MSNPs were used for the incorporation of 
US active PFP. Sonication at 37 kHz with 100 % power for 10 min was helpful 
for PFP liquid to go inside the pores of MSNPs by capillary filling which has 
already been reported in literature155 The reason of using PFP is its low boiling 
point which is 28oC. Incubating PFP with Dox-MSNPs at room temperature led 
to evaporation of extra liquid PFP and keeping liquid PFP inside the pores due 
to capillary forces, which enhance the boiling point of liquid. But combining the 
effect of body temperature (37oC) with ultrasound can cause dislodging and 
vaporization of this liquid from pores and these bubbles are able to give contrast 
by ultrasound. PFP loading after Dox entrapment was beneficent by two ways. 
Firstly, the grafting and functionalization of MSNPs reduce the surface area of 
MSNPs for drug loading  and secondly we have also observed in our 
experiments that pre loading of PFP to MSNPs led to evaporation of PFP during 
the drug loading and particle washing procedure. A very poor or negligible 
ultrasound contrast for such formulations has been observed. To keep PFP 
inside the pores, we have used dried Dox-MSNPs for incubation with PFP. 
Immediately after evaporation of extra liquid PFP dried PFP-Dox-MSNPs were 
coated with lipid layer as mentioned in section 2.2.1.4. For lipid coating we used 





same ratio of lipid to MSNPs which we have already optimized with unloaded 
MSNPs. Lipid layer on the surface of MSNPs supposed to stay intact to keep 
the PFP inside the pores of carrier. These particles were resuspended in water 
for further experiments.  
3.3.3 US Contrast Characterization and Stability 
For optimization of contrast measurement, we have first observed Lip-PFP-
MSNPs without drug loading before extending our studies to drug loaded Lip-
PFP-MSNPs. As mentioned above for simulation and visualization of 
ultrasound contrast a self-made agar phantom fitted with silicon tube was used. 
After dispersing Lip-PFP-Dox-MSNPs in deionized water at concentration of 
MSNPs 1 mg/ml and 100 µl of this sample was further diluted with 100 ml of 
circulating medium, we have observed that our carriers are showing very good 
contrast even at very low concentration of MSNPs 1µg/ml. We have also 
performed the same experiments with non-PFP loaded but lipid coated MSNPs 
and found that they have not given any contrast on exposure to US waves. For 
stability of our Lip-PFP-Dox-MSNPs we have extended our studies for longer 
duration. The purpose of this study was to observe the life span of liquid PFP 
to be intact within pores and its effect on stability of our carriers at room 
temperature. To check the stability and contrast characterization we kept the 
carrier dispersed in purified water at room temperature and at different time 
intervals, including 1 hr, 2 hr, 24 hr, 48 hr, 72 hr, 96 hr and 120 hrs, 100 µl of 
samples were added in circulating medium and US contrast was observed with 
US device. Each sample has given very good contrast even after 120 hrs of 
span, confirming the availability of liquid PFP inside pores, and on exposure to 
US, conversion of this liquid to gaseous form resulting in US contrast as shown 
in figure 29. Our results showed that these PFP loaded MSNPs are stable in 
the absence of US until 5 days and can keep liquid PFP inside pores. Afterward 
the intensity of contrast has been reduced but still it is significant as far as the 
stability of US contrast is concerned.  
As shown in figure 7, we worked with a circulating system to mimic blood 
stream, where individual sample is in circulation and in the later circulation the 





intensity of contrast has been reduced leading to no contrast in the end. These 
results supported our hypothesis that on exposure to US waves the PFP liquid 
inside the pores get vaporized leading to loss of PFP in the form of gas by 
rupturing the lipid layer and at the end giving no more contrast. So by these 
experiments we can say that the lipid coated MSNPs are stable at room 
temperature until they are not exposed to US waves. In comparison, 
microbubbles have also been reported as a good US contrasting agents but 
their life of stability is in the range of few minutes which is a limiting factor and 
in contrast our drug carriers are quite stable for days and become unstable just 
after exposure to US waves.69,74  
 






Figure 29: Representative images US contrast of PFP loaded Lip-MSNPs at different time 
intervals with 3.5MHz and MI 0.7 
 





3.3.4 US Triggered Release 
As mentioned above drug loading of Dox was estimated by UV-
spectrophotometry by comparing the concentration of Dox in the initial solution 
which was used for drug loading to MSNPs and the amount of unentrapped 
Dox in the form of supernatant after centrifugation. Based on these experiments 
the amount of Dox loaded in MSNPs can be easily calculated and same amount 
is further used for drug release profile. As per our experimental section the self-
made phantom agar model was used to perform the drug release profile and 
for simulation purpose PBS pH 7.4 was used as a medium. For comparison we 
have performed drug release experiments on Lip-Dox-MSNPs and Lip-PFP-
Dox-MSNPs without and with US waves respectively. In our experiments we 
have observed that after applying US waves the release of Dox was triggered 
and resulted in faster release of drug and it reached to maximum; 93 % within 
3 hrs as shown in figure 30. In comparison the non-US carriers have shown 
slower drug release and it reached just around 10 % of total amount. We have 
also extended our non-US experiments for longer time and it was observed that 
even after 36 hrs the drug release was about 12-13 % and our findings are 
similar to Xin et. al.50 
 
Figure 30: Representative image of drug release profile of Doxorubicin from Lip-PFP-Dox-
MSNPs with US-irradiation versus Lip Dox-MSNPs without US-irradiation 





So it is evident from our drug release experiments that by introducing PFP in 
the pores and application of US waves to these carriers, the release of drug 
was enhanced. We can assume that thermal or mechanical energy or 
combination of both induces the PFP liquid to be vaporized and produce larger 
volume of gas. This gaseous pressure is not only responsible for the rupturing 
of liposomal coating but also forcing the release of the drug from pores by 
mechanical effects. The thermal induction of US waves on lipid layer can also 
enhance the rupturing effect by acoustic cavitation of lipid layer resulting in no 
more gatekeeping effect at pore opening.88 Furthermore, the use of ultrasound 
contrasting agent upon US-irradiation can decrease the threshold of cavitation 
and cavitation related processes.114  
3.3.5 Drug Leakage 
In order to observe the role of PFP present in Lip-PFP-Dox-MSNPs, drug 
leakage test was performed. This leakage effect was compared with Dox-
MSNPs and Lip-Dox-MSNPs as mentioned in section 3.2.6. The purpose of this 
test was to study the stability of drug inside the pores along with PFP under 
inert conditions. The results in figure 31 showed that the release of Dox from 
Lip-PFP-Dox-MSNPs was faster than Lip-Dox-MSNPs and this higher release 
could be due to instability of PFP inside the pores even at room temperature 
but this release rate was slower than Dox-MSNPs. By these results, we can 
assume that the availability of PFP inside the pores does not have any 
significant role in the release of drug under inert condition but on exposure to 
US-irradiation causing the triggered release, which is evident from drug release 
profile. 
 






Figure 31: Drug release profile of Dox-MSNPs, Lip-Dox-MSNPs and Lip-PFP-Dox-MSNPs 
under inert conditions (non-US) with PBS buffer at 4oC 
 
3.3.6 Morphological Studies Before and After US  
To reveal the effects of US-irradiation on PFP and lipid layer, pre and post US-
irradiation TEM was performed and images are shown in figures 31 and 32. 
Lipid layer was stained with 2% uranyl acetate where dark and bright contrasts 
are representing lipid layer and MSNPs respectively. As we can see in figure 
32 with black arrows, where before US, the lipid layer can be seen in the form 
of dark contrast around the particles in the form of uniform layer. This dark 
contrast is due to uranyl acetate, which made the lipid layer an electron rich 
area. The mesoporous character of the MSNPs cannot be seen and it maybe 
because of the lower magnification. In case of few particles, a lipid bilayer 











Figure 32: TEM micrographs of negatively stained Lip-PFP-MSNPs before US-irradiation 
showing uniform lipid layer around MSNPs 
 
To evaluate the effects of US irradiation on lipid layer the morphology of carriers 
was investigated with TEM and results are shown in figure 33. Here we can see 
that a non uniform layer around the particles, which is indicating the damage of 
lipid layer. The rupturing of one side of lipid layer indicates sudden exertion of 
gas pressure causing lipid opening from weaker side. Furthermore, this higher 
pressure of gas was able to damage the edges of MSNPs as well and causing 
the burst release of Dox. Another possibility would be the conversion of liquid 
PFP in to smaller bubbles sequentially attached to lipid layer and disruption of 
these bubbles by US, ultimately rupture the lipid layer.88 By utilizing these 
reported effects of ultrasound reactive agent along with US-irradiations in our 
studies, we have observed the great difference of Dox release where US-
triggered release of Dox is 9.5 folds higher than non-US. 
 
 






Figure 33: TEM micrographs of negatively stained Lip-PFP-MSNPs after US-irradiation 
showing bursting effects of lipid layer around MSNPs 
 
3.3.7 Measurement of Gas Produced by Vaporization 
The amount of gas produced by liquid PFP was measured with a double syringe 
Luer lock system as mentioned in experimental section. Under US-irradiations, 
2 ml of Lip-PFP-MSNPs dispersion containing 5 mg of MSNPs was able to 
produce 800 µl of gas which was significantly higher than amount of gas 
produced in liposomes.119 Although the entrapped volume of PFP inside pores 
was much lesser but still it has produced such a large volume of gas. That 
would have only be possible if liquid PFP is present and converted to gas 





because the volume of gas produced by same volume of liquid would be much 
higher than the original volume of liquid. On the other side in either case of 
absence of liquid PFP or presence of gaseous PFP inside pores, the amount 
of gas produced would be very low. These results strengthen our hypothesis of 
presence of liquid PFP inside pores, which on US-irradiations was converted to 
gas and ruptured the lipid coating. 
3.3.8 Cell Culture Experiments 
3.3.8.1 Carrier Inertness 
To evaluate the biological compatibility of our system, cell viablility assay was 
performed with drug unloaded carriers. MDA-MB 231 (breast cancer 
adenocarcinoma) cells were incubated overnight with DMEM containing 10 % 
FCS in 5 ml petridish at 50x104 cells/cm2. For this study we have divided our 
carriers in 4 different categories including MSNPs, Lip-MSNPs, Lip-PFP-
MSNPs (Non-US) and Lip-PFP-MSNPs (US). The purpose of this study was to 
evaluate the toxic effects of not only MSNPs and Lip-MSNPs but also the 
effects of US waves and PFP on the cells. Different concentrations (250 µg/ml, 
500 µg/ml, 750 µg/ml and 1000 µg/ml of MSNPs) of all above four formulations 
in triplicate were incubated for 4 hrs keeping US-irradiated cells as blank. After 
removing the formulation, fresh medium was added to petri dishes and Lip-
PFP-MSNPs (US) was exposed to US by using eZono device for 5 min for each 
plate. MTT assay was performed after overnight incubation and it has been 
observed that all the above mentioned formulations have not shown significant 
cellular toxicity. Maximum of toxicity produced by Lip-PFP-MSNPs (US) and 
Lip-PFP-MSNPs (Non-US) was  about 7 % even at highest concentration of 
1000 µg/ml of MSNPs. Although we have used lower concentrations of MSNPs 
in our drug-loaded carrier experiments. So we found that all our carriers, with 
good biocompatibility and safety, are suitable for further experiments without 
causing toxicity to cells and our results regarding safety of MSNPs are similar 
to findings in the literature.73 Here we have used cells with medium (US) as 
blank and the results regarding inertness of our carriers are shown in figure 
34 A.  





Before extending our studies to drug loaded carriers it was necessary to 
perform cytotoxicity experiments with pure drug. For this purpose we have 
selected different concentrations of Dox divided in two different groups (US and 
Non-US) in triplicate. To evaluate the sono-sensitivity of the drug the above 
mentioned procedure of US application was adopted and MTT assay was 
performed. Here we have found that different concentrations of Dox, 
irrespective of US waves, have shown same toxicity as shown in figure 34 B. 
Hence it was observed that US waves don’t have any significant effect on Dox 
cytotoxicity. 






Figure 34: Cytotoxicity evaluation of (A) carriers (MSNPs, Lip-MSNPs, Lip-PFP-MSNPs with 
and without US-irradiation) and (B) Dox with and without US-irradiation (5 min, 12 MHz, MI 1.4) 
by using MTT assay with different concentrations. In both cases US-irradiated cells with 
medium were taken as blanks 
 
 





3.3.8.2 MTT Assay 
After evaluation of inertness of our empty carriers and non-significant effect of 
US waves on Dox toxicity we have extended our studies to drug loaded carriers. 
In this part of study, we have divided our formulations in two main categories 
based on PFP (US reactive agent) incorporation. In first category, there was no 
PFP incorporation and it consists of two subdivisions (US and Non-US). 
Similarly, second category was based on the presence of PFP with further 
subdivisions (US and Non-US). All these formulations were subjected to cell 
viability assay by using the same protocol mentioned above with pure Dox as 
positive control. After 4hr incubation, the cells have taken up the carriers and 
on exposure to US waves, it has shown very significant effects. The results as 
in figure 35, showed that Lip-PFP-Dox-MSNPs (US) had highest cytotoxicity as 
compared to all other formulations. This higher cytotoxicity is supporting the 
evidence of in-vitro triggered release by US-irradiations.  
We observed that Lipid-Dox-MSNPs (Non-US) has shown minimum of toxicity 
and this lower effect could be due to lesser release of the drug inside the cell 
after 4 hr incubation. Although cellular uptake of the Dox has been enhanced 
by lipid coating of Dox-MSNPs but still it was not able to release full of Dox. On 
the other side Lip-Dox-MSNPs (US) and Lip-PFP-Dox-MSNPs (Non-US) has 
shown more toxicity but these effects are quite similar to each other. The 
relative faster release of DOX from Lip-Dox-MSNPs (US) and Lip-PFP-Dox-
MSNPs (Non-US) is due to the effects of US waves and presence of PFP 
respectively, which have shown higher cytotoxic effects of above mentioned 
formulations as compare to the formulation without any PFP and US waves. 
We can assume that a very small part of PFP inside the pores of Lip-PFP-Dox-
MSNPs vaporized and cause some of the drug to release even in the absence 
of US waves and this release was higher than release of Dox in Lip-Dox-
MSNPs resulting in more toxicity. Similarly, the higher cytotoxicity of Lip-Dox-
MSNPs (US) as compare to toxicity of Lipid-Dox-MSNPs (Non-US) could be 
due to higher release of drug from the carrier by US waves. Although the exact 
reason of these results is not known and we can assume that higher release of 
the drug is because of some vibrational movements of porous structure due to 
energy provided by mechanical effects of US waves. The toxicities of Lip-Dox-





MSNPs (US) and Lip-PFP-Dox-MSNPs (Non-US) are lesser than the toxicity 
produced by Lip-PFP-Dox-MSNPs (US) because in later we have incorporated 
PFP, vaporized by thermal and mechanical effects of US waves. US waves, 
with FDA approved MI 1.4 and frequency of >10 MHz for clinical purposes, 
have tendency to penetrate to the surface tissues86,156 and after the uptake of 
our carriers by the cells, it has produced some significant results. The PFP 
inside pores of carrier, being prone to be disturbed by US-irradiation, can trigger 
the release of the drug inside cells.86,87 As a result, Lip-PFP-Dox-MSNPs (US) 
have shown more toxicity as compared to all other three formulations. Hence, 
it is revealed from cytotoxic studies that by combining effects of PFP inside the 
pores of MSNPs and US waves together, the release of drug has been 
enhanced in in-vitro tumor cells and it can produce more cytotoxic effects. 
 
 
Figure 35: In vitro cytotoxicity studies by MTT assay, showing effects of Dox loaded carriers to 
MDA-MB-231 cells. A comparative cytotoxic effects of US-irradiated (5 min, 12 MHz, MI 1.4) 
and non-US, Lip-Dox-MSNPs and Lip-PFP-Dox-MSNPs where the US-irradiated Lip-PFP-Dox-











3.3.8.3 Cellular Uptake Studies 
To strengthen our hypothesis that the release of the drug was enhanced by US 
waves after internalization of our carrier in cells, we have performed cellular 
uptake studies to observe these cells under fluorescence microscope and 
results are shown in figure 36. Higher cellular uptake of lipid coated MSNPs 
has already been reported by researchers where lipid layer, due to its 
biocompatibility, enhanced the delivery of the drug carriers.49,157 For uptake 
studies and internalization, we have used three different formulations including 
Dox-MSNPs, Lip-Dox-MSNPs and Lip-PFP-Dox-MSNPs (US). In this case, we 
have used lower concentrations of Dox to avoid the toxicity effects as the 
incubation period was 4 hrs. After giving US waves and fixation of cells, nuclei 
stained cells were observed under CLSM for the localization of green and red 
fluorescence as in figure 36. Red fluorescence is characteristic of Dox and 
green of FITC labelled MSNPs and here we observed that localization of green 
fluorescence in the cytoplasmic region has shown the efficient uptake of carrier 
by the cells. Internalization of MSNPs is more in Lip-Dox-MSNPs (Non US) and 
Lip-PFP-Dox-MSNPs (US) as compare to Dox-MSNPs and this is due to the 
lipid coating of MSNPs which has enhanced the cellular uptake. Dox 
localization in the cells is also showing the uptake pattern as mentioned above. 
If we observe the release pattern of Dox in the cells Dox-MSNPs has shown 
the lesser release than lipid coated formulations. The results have shown that 
the drug release was enhanced in Lip-PFP-Dox-MSNPs and this release is 
because of triggering effect of US waves. So this intracellular release pattern is 
supportive to in-vitro release studies where we got enhanced release effects 
triggered by US waves. 
 






Figure 36: Cellular uptake studies by confocal microscopic images of MDA-MB-231 cell line 
after 4hr incubation at 37oC with FITC (green) labelled Dox-MSNPs, Lip-Dox-MSNPs (Non-US) 
and Lip-PFP-Dox-MSNPs (US), showing internalization of Dox (red) in nuclear region which 
was stained with DAPI (blue) with scale bar of 20µm. Higher internalization of Dox with Lip-
Dox-MSNPs showed higher cellular uptake due to lipid coating and even higher internalization 
and triggered release Dox in Lip-PFP-Dox-MSNPs is due to presence of lipid layer and US-
irradiation 






3.4 Co-Delivery of CA-IX inhibitor and Dox in Hypoxia  
3.4.1 Preparation of Lipc 
Liposomes as carriers for CA-IX inhibitor, were prepared by thin layer hydration 
method and same molar mass ratios of DPPC:Chloesterol:DOTAP (85:12:3) 
were used. CA-IX inhibitor as a hydrophobic agent was expected to be loaded 
in lipid bilayer. These CA-IX inhibitor liposomes (Lipc) were initially 
characterized by dynamic light scattering for size distribution and laser Doppler 
velocimetry for surface charge.  Initially, 2 mM of CA-IX inhibitor liposomes were 
prepared and the size was 309 ± 24.93 (nm) which was much higher than we 
required for MSNPs coating. The PDI and zeta potential for above mentioned 
liposomes were 0.54 ± 0.03 and 20.90 ± 0.81 (mV) respectively.   Later the size 
reduction was observed with lower concentration of CA-IX inhibitor that was 
20 µM. Here it was noticed that the size of Lipc characterized with DLS was 
109.20 ± 9.69 (nm) with PDI 0.21 ± 0.14 which was in the desired range. 
Although the reason for this size reduction was unclear but concentration 
dependent size and PDI reduction was in accordance to previous report.158 
Surface charge of Lipc was also a critical factor to be characterized, for coating 
negatively charged MSNPs. The surface charge of Lipc observed by LDV was 
+23.50 ± 7.51 (mV) which was also helpful for the coating of MSNPs. 
3.4.2 Morphological Studies (AFM) 
After liposome preparation and characterization, next step was to characterized 
lipid coating to MSNPs. The Lipc coating to MSNPs was initially visualized by 
AFM and micrographs are shown in figure 37. Here we can see the Lipc-Dox-
MSNPs were in the range of 100-150 nm and not completely round. These non-
round structures are the characteristic feature of MSNPs and these findings are 
similar to previous reports.159 Uniform layers can be observed over MSNPs 
which is indicating the coating of lipid to MSNPs was successfully attained. As 
this technique involves the interaction of cantilever tip with sample and causes 
the damage or deformation of soft structures like liposomes. This feature of 





AFM was helpful to visualize the lipid coating as indicated with arrows in figure 
37 (A,C & D). These images are similar to the images previously reported for 
the lipid coated particles where incomplete lipid layer was observed around the 
particles under AFM.160 
 
 
Figure 37: AFM images of Lipc-MSNPs (A) amplitude trace, (B) phase trace (C & D) amplitude 
trace showing lipid coating of MSNPs. 
 
3.4.3 Preparation of Lipc-Dox-MSNPs 
As the size and surface charge of Lipc were in the same range as for blank 
liposomes so it was expected that Lipc can be easily loaded to Dox-MSNPs. 
The Dox-MSNPs prepared with mass ratio of Dox/MSNPs 0.51 were used for 
the development of Lipc-Dox-MSNPs. For the preparation of Lipc-Dox-MSNPs 
the same procedure was adopted by using same molar mass ratios of 
MSNPs:Liposome 1:0.70. As here the fixed lipid to MSNPs ratio was used so 





the concentration of CA-IX inhibitor with Dox to be in effective range was 
necessary.   
3.4.4 Cell Culture Experiments 
3.4.4.1 Extracellular acidification Test 
Hypoxic condition of the cells is directly associated with extracellular pH 
regulation, which results in reduced efficacy of chemotherapy and radiotherapy. 
Activity of CA-IX is one of the key factors for extracellular acidic environment. 
To evaluate the effects of CA-IX inhibitor on the extracellular acidic pH, cells 
were treated with different formulations containing CA-IX inhibitor under 
hypoxic and normoxic conditions.161 As results shows in figure 38 that by 
inhibiting CA-IX enzyme in hypoxia, an increase in extracellular pH has been 
observed. This effectiveness in pH change is only possible in hypoxic 
conditions where enzyme is overexpressed and activated in lower oxygen 
supply.123 The data indicated that under hypoxia, CA-IX was activated but with 
the treatment of CA-IX inhibitor the extracellular acidosis has been reduced. 
We also observed that there was no significance change in extracellular pH 
under normoxic conditions even after treating with CA-IX inhibitor. This also 
indicates that the inhibition of CA-IX enzyme is linked with its overexpression in 
hypoxic conditions where it maintains the balance between internal alkaline and 
external acidic environment. 
 
Figure 38: Extracellular acidification in normoxia and hypoxia before and after traetment with 
CAI, Lipc and Lipc-Dox-MSNPs after (A) 4 hr and (B) 24 hr incubation 
 





3.4.4.2 Western Blotting (HIF-1α and CA-IX) 
To validate the over expression of CA-IX enzyme, protein expression analysis 
by western blot technique was performed. MDA-MB231 cells are reported to 
express large amounts of CA-IX enzyme under hypoxic conditions.162 For the 
effectiveness of CA-IX enzyme inhibitor, it was necessary to confirm the over 
expression of CA-IX enzyme. HIF-1α is another indicator, normally over 
expressed in hypoxic conditions. The results of western blots for normoxic and 
hypoxic cells are shown in figure 39 and it can be observed in 39 A that both 




Figure 39: Western blots of normoxic and hypoxic cells for  (A) CA-IX expression and HIF-1α 
expression, (B) CA-IX expression after treatment 
 
As it can be noticed in figure 39 B, after 24 hr treatment with CA-IX inhibitor no 
significant effects were observed under normoxic conditions. A significant 
difference in CA-IX expression was observed in hypoxia between treated and 
non-treated samples. Cells treated with CA-IX inhibitor, Lipc and Lipc-Dox-
MSNPs have shown lesser expressions as compared to Blank cells and these 
results could be due to the inhibition of CA-IX enzyme. In normoxic conditions 
treated and non-treated cells have shown no significant difference because CA-
IX enzyme was not overexpressed. Hypoxic conditions mimic the expression of 










3.4.4.3 In-vitro Cytotoxicity Assay (MTT Assay) 
Many of the chemotherapeutic agents, which are specifically designed for 
targeting of highly proliferating cells, fail even after reaching to hypoxic cells. 
The effective concentration of drugs taken up by the tumor cells is prerequisite 
for suitable outcomes.165 Initially we performed our cell viability studies to 
evaluate cytotoxic effects of pure Dox with and without CA-IX inhibitor and Lipc 
both in normoxia and hypoxia. The cytotoxic effects of Dox after 4 hr and 24 hr 
incubation with MDA-MBA 231 cells, pre-treated with CA-IX inhibitor and Lipc 
for 4 hrs in normoxia and hypoxia, are shown in figure 40. The concentration of 
Dox was 100 µg/ml and for CA-IX inhibitor was 360 nM. Here we have observed 
that pure Dox has shown more cytotoxic effects in normoxia with 4 hr incubation 
period as compared to hypoxia. Similar kind of results were observed with 24 
hr Dox incubation time. The lower cytotoxic effects of Dox in hypoxia are due 
to extracellular acidosis as we have observed in extracellular acidification test. 
This acidic environment cause ionization of weakly basic drug like Dox and 
results in lesser cellular uptake of drug. Another possibility for lesser Dox 
toxicity in hypoxia would be because of suppression of ROS mediated 
cytotoxicity of Dox in hypoxia,166 as already reported.167,168 Contrarily these 
results were different to those we got after inhibition of CA-IX. After treatment 
with pure CA-IX, Dox with 4 hrs incubation has shown no significant difference 
in cytotoxicity between normoxia and hypoxia but after 24 hrs Dox incubation it 
has shown better results where in hypoxia more cytotoxic effects of Dox has 
been observed as compared to normoxia. 






Figure 40: In-vitro cytotoxicity evaluation of Dox (4 hr & 24 hr incubation) with CAI and Lipc 
pretreated cells in normoxia and hypoxia 
 
When the cells were treated with Lipc before incubation with Dox, the more 
significant results have been observed. We found that even after 4 hr incubation 
in hypoxia pre-treated with Lipc, Dox has shown more toxic effects as compared 
to pure CA-IX inhibitor in hypoxia. By these findings, it can be established that 
in hypoxic conditions inhibition of CA-IX enzyme is beneficent for more cytotoxic 
effects of Dox and these effects can be further enhanced by loading CA-IX 
inhibitor to liposome. The better results with liposomes, as previously 
reported,169 are because of higher biocompatibility and internalization due to 
structure of lipid layer. After establishing this fact next step was to evaluate the 
cytotoxic effects of Lipc-Dox-MSNPs in hypoxic environment. 
 






Figure 41: In-vitro cytotoxicity of Lipc-Dox-MSNPs, Lip-Dox-MSNPs and Dox after 4 hr & 24 hr 
incubation in normoxia and hypoxia 
 
In this part of studies, as shown in figure 41, similar kind of pattern has been 
observed where pure Dox in hypoxia has shown lesser cytotoxic effects due to 
ionization and suppression of ROS-mediated toxicity of Dox, both after 4 hr and 
24 hr incubation. Here the same concentrations of Dox 100 µg/ml and CA-IX 
inhibitor 360 nM were used. Lipc-Dox-MSNPs has shown more cytotoxic effects 
in hypoxia as compared to normoxia both after 4 hr and 24 hr incubation. On 
the other hand, Lip-Dox-MSNPs has shown almost same cytotoxic effects in 
hypoxia and normoxia after 4 hr incubation. Along with 24 hr incubation of Lip-
Dox-MSNPs have also shown same pattern in hypoxia and normoxia. As a 
cross comparison between Lipc-Dox-MSNPs and Lip-Dox-MSNPs, in normaxia 
with 4 hr and 24 hr incubation, there is no significant difference but when we 
compare Lipc-Dox-MSNPs and Lip-Dox-MSNPs in hypoxic conditions, 
significant difference can be observed with more Lipc-Dox-MSNPs cytotoxic 
effects. These results are also indicating that CA-IX inhibitor can show its 
effects only in hypoxia when CA-IX is over expressed. Our findings are in 
accordance with previously established results103,170 where the effects of Dox 





in combination with CA-IX inhibition has produced better cytotoxic effects. By 
these synergistic effects of Lipc-Dox-MSNPs we can assume that CA-IX 
inhibitor and Dox loaded drug delivery system is a suitable system for the 





























4  Summary & Outlook 
 





4.1 Summary and Outlook 
In this dissertation, different types of nanoconstructs, including MSNPs and 
liposomes were fabricated for the development of an advanced drug delivery 
system which can deliver both hydrophilic and hydrophobic drugs to the tumor 
cells with better efficacy and biocompatibility and minimized side effects to 
healthy tissues. The candidature of MSNPs as nanocarriers with potential 
features, supported with lipid layer was explained in introduction part along with 
their merits and demerits. The combined effects of liposomes and MSNPs in 
sustained release or stimuli responsive drug delivery systems equipped with 
literature were highlighted. This project was mainly divided in to four major parts 
where nanocarriers were characterized and further evaluated for in-vitro 
analysis under different conditions such as normoxia and hypoxia. 
In the first part, MSNPs of different molar mass ratios of surfactant/silica were 
fabricated. The parameters which can affect the particle size distribution, were 
evaluated. These MSNPs for their physicochemical properties were initially 
characterized by Dynamic Light Scattering (DLS) for size distribution and Laser 
Doppler Velocimetry (LDV) for surface charge. The removal of surfactant for 
the generation of porous structure, was evaluated with elemental analysis and 
surface charge. Surface area characterization of MSNPs were evaluated with 
nitrogen sorption desorption method, where the suface area and surface 
volume were influence by duration of extraction for surfactant removal. The 
morphological structures were characterized by different microscopies 
involving Atomic Force Microscopy and Electron microscopies. The 
morphological studies performed with AFM were in accordance to the size 
distribution obtained by DLS. The porous structure of MSNPs was observed 
with electron microscopies. Tranmission electron microscopy (TEM) has shown 
that the MSNPs are more or less round in shape with ordered porous structure. 
The pore size evaluated with TEM was the same as it was characterized with 
sorption-desorption pore size measurement. For further confirmation of porous 
structure of MSNPs, Scanning Transmission Electron Microscopy (STEM) was 
performed and particle size and porous distribution were evaluated. 





In the work described in second chapter, a lipid coated MSNPs system was 
designed and characterized for further investigations. Cationic liposomes 
prepared with thin layer hydration technique and its coating to MSNPs was 
characterized with hydrodynamic size, surface charge and FTIR spectrum. 
Lipid coating of MSNPs were further visualized with Cryo-TEM & TEM 
micrographs. Higher surface area of MSNPs with higher drug loading capacity 
made them suitable candidate for the delivery of large amounts of drugs. In-
vitro drug release profile has shown sustained release effects where the rate of 
drug release from bared drug loaded MSNPs was faster than lipid coated ones. 
The lipid coating to MSNPs with reduced premature drug release under inert 
conditions addressed the issue of premature drug leakage. In a comparative 
study of in-vitro cytotoxic profile, lipid coated MSNPs due to higher 
biocompatibility delivered higher concentrations of Dox and has shown more 
cytotoxic effects as compared to bared MSNPs. These higher cytotoxic effects 
with lipid coated MSNPs were further evaluated with Confocal Laser Scanning 
microscope where higher internalization of Dox in the cells was evident for the 
higher uptake of the carriers. 
In the third chapter, we have successfully developed a stimuli responsive smart 
drug delivery system composing of lipid coated MSNPs as a carrier, Dox as a 
model drug, US as a stimulus and PFP as a stimuli responsive agent. By 
combining MSNPs with liposomes, very significant results have been produced 
due to the morphology and unique structure of the MSNPs along with 
biocompatibility and gatekeeping effects of liposomes. PFP was successfully 
incorporated inside the pores of MSNPs by capillary filling and very stable 
nanocarriers were produced. The US-irradiation, with FDA approved 
specifications, has produced very satisfactory triggered release effects due to 
rupturing of lipid layer by the gaseous pressure of vaporized PFP inside pores. 
In-vitro cell culture experiments have shown higher internalization of carrier due 
to biocompatibility of lipid layer and higher cytotoxic effects due to triggered 
release by US-irradiations. These smart nanocarriers, can be used as drug 
delivery system for many chemotherapeutics for site-specific triggered release 
of drug to enhance the efficacy and to avoid undesired side effects to healthy 
tissues. 





The fourth chapter of this study was based on the development of a co-delivery 
system of carbonic anhydrase IX inhibitor and Dox, where carbonic anhydrase 
inhibitor loaded liposomes were coated to Dox loaded MSNPs. In-vitro cytotoxic 
experiments were performed under normoxia and hypoxia and it was evaluated 
that Carbonic anhydrase IX enzyme was overexpressed under hypoxic 
conditions. The enzyme inhibitor can be effective only when enzyme is 
overexpressed in hypoxia. Furthermore, the combined effects of enzyme 
inhibitor and Dox has produced synergistic cytotoxic effects under hypoxia due 
to inhibition of carbonic anhydrase IX enzyme. Better inhibition effects of 
carbonic anhydrase IX inhibitor loaded liposomes were observed as compared 
to pure enzyme inhibitor, although these findings are on the initial stage and 
need further to be investigated. 
In future, the aim of the study will be to perform in-vivo evaluation of drug 
delivery carriers, involving biodistribution of drug and carriers in different 
organs. The in-vivo studies will also involve the stimuli US-responsive triggered 
release in animal model. As for MSNPs as drug carriers are concerned we are 
looking forward to develop new drug delivery system for another drug like 
photosensitizer. This system will be a stimuli responsive advanced drug 
delivery system where US would trigger the release of drug and light will 
activate the drug to produce cytotoxic effects. As hypoxic experiments are in 
early stages, so we will extend our studies in hypoxic condition for further 
validation of already developed system and to evaluate photodynamic effects 
under oxygen deprived environment. 
  





4.2 Zusammenfassung und Ausblick 
Diese Promotionsarbeit beschäftigte sich mit der Herstellung verschiedener 
Nanomaterialien, einschließlich mesoporöser Silikananopartikel (MSNPs) und 
Liposomen, um daraus ein neuartiges Arzneistoffträgersystem zu entwickeln. 
Das sowohl hydrophile als auch lipophile Arzneistoffe zu Tumorzellen 
transportieren kann und dabei, im Hinblick auf die Arzneistoffe, eine 
Verbesserung der Biokompatibilität, eine höhere Effektivität und weniger 
Nebenwirkungen auf gesundes Gewebe aufweist. In der Einleitung wurde auf 
die Vorzüge und Nachteile der MSNPs als Nanoträgersysteme und in 
Kombination mit Lipidbeschichtungen näher eingegangen. Eine genauere 
Erklärung der Kombinationseffekte von Liposomen und MSNPs bei 
Retardträgersystemen oder stimuli-responsiven Trägersystemen unter 
Zuhilfenahme der Fachliteratur folgte. Das vorliegende Projekt lässt sich in vier 
Kapitel einteilen. Hier wurden die Trägersysteme eingehen charakterisiert und 
auf ihre Eigenschaften unter verschiedenen in-vitro Bedingungen, wie z.B. 
Normoxie und Hypoxie, eingegangen. 
Das erste Kapitel beschreibt die Herstellung der MSNPs unter Verwendung 
verschiedener Molmassenverhältnisse von Tensid zu Silika, zur Evaluation der 
die Partikelgrößenverteilung beeinflussenden Parameter. Als erste 
Charakterisierungsmöglichkeit der physikochemischen Eigenschaften diente 
dabei die Messung der Partikelgröße mit Hilfe der Dynamischen Lichtstreuung 
(DLS) und die Messung der Oberflächenladung durch die Lader Doppler 
Velocimetrie (LDV). Die Entfernung des verwendeten Tensids, um die poröse 
Struktur zu erzeugten, wurde durch Elementaranalyse und 
Oberflächenladungsmessungen bestimmt. Die Untersuchung der Oberfläche 
der MSNPs erfolgte mit Hilfe der Messung von Sorption und Desorption von 
Stickstoff, dabei wurden die gemessene Fläche und das Volumen von der 
Extraktionszeit des Tensids beeinflusst. Verschiedene mikroskopische 
Techniken, wie die Raster-Kraft- und die Elektronenmikroskopie, dienten der 
Charakterisierung der Morphologie der Trägersysteme. Die Ergebnisse der 
Größenvermessungen nach Raster-Kraft-Mikroskopie waren dabei in 
Übereinstimmung zu den Ergebnissen der Größenmessung mit Hilfe der DLS. 





Unter Elektronenmikroskopen konnte außerdem die poröse Struktur der 
MSNPs beobachtet werden. Die Transmissionselektronenmikroskopie (TEM) 
zeigte, dass die MSNPs von mehr oder weniger runder Form waren und eine 
geordnete poröse Struktur aufwiesen. Die dabei gemessene Porengröße 
entsprach der Porengröße, die mit Hilfe der Sorptions-Desorptionsmethode 
bestimmt wurde. Zur genaueren Betrachtung der Porenstruktur und zur 
Vermessung der Porengröße und verteilung, kam außerdem ein 
Rastertransmissionselektronenmikroskop (STEM) zum Einsatz. 
Das zweite Kapitel beschreibt das Design und die Charakterisierung 
lipidüberzogener MSNPs als Trägersysteme. Kationische Liposomen, 
hergestellt mit Hilfe der Filmbildungsmethode, und mit ihnen überzogene 
MSNPs wurden dabei auf ihre hydrodynamischen Durchmesser, ihre 
Oberflächenladung und ihr FTIR-Spektrum untersucht. Die Lipidhülle der 
MSNPs konnte außerdem mit Hilfe von cryo-TEM- und TEM-Aufnahmen 
visualisiert werden. Die große Oberfläche der MSNPs und der daraus 
folgenden hohen Beladungskapazität für Arzneistoffe, macht sie zu einem 
interessanten Kandidaten für den Transport hoher Arzneistoffmengen. Die in-
vitro Freisetzungskurve des Arzneistoffes Doxorubicin (Dox) zeigte eine 
verzögerte Abgabe des Arzneistoffes, wobei die Freisetzung aus nicht 
überzogenen Trägersystemen schneller war, als die aus den lipidüberzogenen. 
Daher konnte mit Hilfe des Lipidüberzuges das Problem der frühzeitigen, 
ungewollten Arzneistoffabgabe unter Lagerungsbedingungen gelöst werden. 
Eine vergleichende in-vitro Studie zur Zelltoxizität konnte zeigen, dass die 
lipidüberzogenen MSNPs aufgrund ihrer höheren Biokompatibilität höhere 
Doxorubicinkonzentrationen in die Zellen bringen konnten und daher einen 
stärkeren zytotoxischen Effekt als die nicht überzogenen MSNPs aufwiesen. 
Ein Nachweis dieses verstärkten Effektes erfolgte auch mit der konfokalen 
Laser-Scanning-Mikroskopie. Hier zeigte sich eine stärkere Internalisation von 
Dox als klarer Hinweis auf eine stärkere Aufnahme der Trägersysteme in die 
Zellen. 
Im dritten Kapitel konnte ein stimuli-responsives Trägersystemen erfolgreich 
entwickelt werden. Dazu dienten lipidüberzogene MSNPs als Trägersysteme, 





Dox als Modellarzneistoff, Ultraschall (US) wurde als Stimulus verwendet und 
Perfluorpentan (PFP) war das auf den Stimulus reagierende Agens. Die 
Kombination von Liposomen und MSNPs ergab aufgrund der besonderen 
Struktur der MSNPs in Kombination mit der guten Biokompatibilität und dem 
Gatekeeping-Effekt der Liposomen sehr gute Ergebnisse. Der Einschluss von 
PFP in die Poren der MSNPs gelang durch Kapillarfüllung und es entstanden 
sehr stabile Nanoträgersysteme. Eine US-Behandlung mit von der FDA 
zugelassenen Spezifikationen löste eine sehr zufriedenstellende gezielte 
Freisetzung des Arzneistoffes aus. Dabei konnte ein Zerreißen der Lipidhülle, 
aufgrund des hohen Druckes der entstehenden Dämpfe des PFP innerhalb der 
Poren der MSNPs, beobachtet werden. Die durchgeführten in-vitro 
Zellkulturversuche konnten eine höhere Aufnahme aufgrund besserer 
Biokompatibilität bei den lipidüberzogenen Trägersystemen und einen 
stärkeren zytotoxischen Effekt nach gezielter Freisetzung des Arzneistoffes 
durch US nachweisen. Diese intelligenten Nanoträgersysteme sind für viele 
Chemotherapeutika einsetzbar und sorgen durch ihre gezielte Freigabe des 
Arzneistoffes direkt im betroffenen Gewebe für besser Effektivität des 
Arzneistoffes und geringe unerwünschte Nebeneffekte auf gesundes Gewebe.  
Die Basis des vierten Kapitels dieser Studie war die Entwicklung eines 
Trägersystems für den kombinierten Transport von Doxorubicin und eines 
Inhibitors der Carbonischen Anhydrase IX. Dabei wurde der Inhibitor in den 
Lipidfilm der Liposomen eingeschlossen, die als Überzug für mit Doxorubicin 
beladene MSNPs dienten. In-vitro Untersuchungen zur Zelltoxizität wurden 
unter Normoxie und Hypoxie durchgeführt. Dabei wurde auch nachgewiesen, 
dass das Enzym Carbonische Anhydrase IX unter hypoxischen Bedingungen 
überexprimiert wird, sodass der Inhibitor effektive Ergebnisse erzielen kann, da 
er nur bei überexprimiertem Enzym seinen Effekt entfaltet. Auch konnte eine 
synergistische Kombination von Dox und dem Inhibitor der carbonischen 
Anhydrase IX unter hypoxischen Bedingungen dargestellt werden. Höhere 
Inhibitionseffekte gegen die Carbonische Anhydrase IX wiesen 
inhibitorbeladene Liposomen im Vergleich zu freiem Inhibitor auf. Diese 
Ergebnisse sind allerdings noch in einem initialen Stadium und bedürfen daher 
einer weiteren Prüfung. 





Für zukünftige Studien ist es das Ziel eine in-vivo Evaluation des 
Trägersystems vorzunehmen.  Dabei soll die Biodistribution des Trägersystems 
und des Arzneistoffes in den verschiedenen Organen untersucht werden. Die 
gezielte Freisetzung nach Stimulation durch US wird auch in in-vivo 
Tierversuchen geprüft. Im Bereich der MSNPs ist es das Ziel diese als 
Trägersysteme für andere Arzneistoffe wie zum Beispiel Photosensitizer zu 
entwickeln. Somit kann ein stimuli-responsives Trägersystem aufgebaut 
werden, bei dem die Arzneistofffreisetzung durch US und die 
Arzneistoffaktivierung und damit der zelltoxische Effekt durch Licht gesteuert 
werden kann. Eine Weiterführung der Experimente zur Hypoxie, die sich noch 
in einem sehr frühen Stadium befinden, sind ebenso geplant, wie weitere 
Untersuchungen unter hypoxischen Bedingungen für die Evaluation des 




























5.1 List of Abbreviations 
WHO  World Health Organization 
DDS  Drug Delivery System 
FDA  Food and Drug Administration 
MSNPs Mesoporous Silica Nanoparticles 
CMC  Critical Micelles Concentration 
PAA  Poly Acrylic Acid 
PLGA  Poly (Lactide-co-Glycolide) 
PGA  Polyglycolic Acid 
PLA  Poly Lactic Acid 
PEG  Polyethylene Glycol 
MLVs  Multilamellar Vesicles 
ULVs  Unilamellar Vesicles 
LUVs  Large Unilamellar Vesicles 
SUVs  Small Unilamellar Vesicles 
DOTAP 1,2-dioleoyl-3-trimethylammonium-propane  
DOPS  1,2-dioleoyl-sn-glycero-3-phospho-L-serine  
DPPC  1,2-dipalmetoyl-sn-glycero-3-phosphocholine  
Dox  Doxorubicin 
MNPs  Magnetic Nanoparticles 
US  Ultrasound 
NIR  Near Infrared 
ROS  Reactive Oxygen Specie 
MI  Mechanical Index 





CA-IX  Carbonic Anhydrase IX 
pHi  Intracellular pH 
pHe  Extracellular pH 
CTAB  Cetyltrimethylammonium Bromide  
TEOS  Tetraethylorthosilicate 
IEP  Isoelectric Point 
PFP  Perfluoropentane 
PBS  Phosphate Buffer Saline 
DLS  Dynamic Light Scattering 
LDV  Laser Doppler Velocimetry 
Dox-MSNPs    
Doxorubicin loaded Mesoporous Silica Nanoparticles 
Lip-Dox-MSNPs  
Lipid coated Doxorubicin loaded mesoporous silica  
nanoparticles 
Lip-PFP-Dox-MSNPs  
Lipid Coated Doxorubicin and Perfluoropentane Loaded 
Mesoporous Silica Nanoparticles 
Lip-PFP-Dox-MSNPs (US) 
Ultrasound Irradiated Lipid Coated Doxorubicin and 
Perfluoropentane Loaded Mesoporous Silica Nanoparticles 
Lip-PFP-Dox-MSNPs (US)  
Ultrasound Irradiated Lipid Coated Doxorubicin and 
Perfluoropentane Loaded Mesoporous Silica Nanoparticles 
Lipc  CA-IX Inhibitor Liposomes  
 






Doxorubicin Loaded Mesoporous Silica Nanoparticles Coated 
with Carbonic Anhydrase IX Inhibitor Loaded Liposomes 
 
AFM  Atomic Force Microscopy 
TEM  Transmission Electron Microscopy 
FFT  Fast Fourier Transform  
IFFT  Inverse Fast Fourier Transform  
SEM  Scanning Electron Microscopy 
STEM  Scanning Transmission Electron Microscopy 
Cryo-TEM Cryogenic Transmission Electron Microscopy 
FTIR  Fourier Transform Infrared 
BET  Brunauer Emmett Teller 
BJH  Barret Joyner Halenda 
CLSM  Confocal Laser Scanning Microscope 
PDI  Polydispersibilty Index 
FITC  Fluorescein-5 isothiocyanate 
APTES 3-aminopropyl triethoxysilane 
HAADF High Angle Annular Dark Field 
MWCO Molecular Weight Cuttoff  
DMEM Dulbecco’s Modified Eagle’s Medium  
NEA  Non-Essential Amino Acids 
RPMI  Rosewell Park Memorial Institute 
FCS  Fetal Calf Serum 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide  
DMSO Dimethylsulfoxide 





DAPI  4’, 6-diamidino-2-phenylindole 
HIF  Hypoxia Inducing Factor 
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